<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01//EN" "http://www.w3.org/TR/html4/strict.dtd">
<!--
-->
<!-- %html{'xmlns'=>'http://www.w3.org/1999/xhtml', 'xml:lang'=>'en', 'lang'=>'en'} -->
<html>
<head>
<script type="text/javascript">window.NREUM||(NREUM={});NREUM.info={"beacon":"beacon-1.newrelic.com","errorBeacon":"jserror.newrelic.com","licenseKey":"d64d3db899","applicationID":"125361","transactionName":"dAkNQBFbXFUEREkBCVQTDlENQB9dDlUTCANZEkxHC1tH","queueTime":0,"applicationTime":3230,"ttGuid":"","agentToken":null,"agent":"js-agent.newrelic.com/nr-298.min.js","extra":""}</script>
<script type="text/javascript">window.NREUM||(NREUM={}),__nr_require=function a(b,c,d){function e(f){if(!c[f]){var g=c[f]={exports:{}};b[f][0].call(g.exports,function(a){var c=b[f][1][a];return e(c?c:a)},g,g.exports,a,b,c,d)}return c[f].exports}for(var f=0;f<d.length;f++)e(d[f]);return e}({"4O2Y62":[function(a,b){function c(a,b){var c=d[a];return c?c.apply(this,b):(e[a]||(e[a]=[]),void e[a].push(b))}var d={},e={};b.exports=c,c.queues=e,c.handlers=d},{}],handle:[function(a,b){b.exports=a("4O2Y62")},{}],YLUGVp:[function(a,b){function c(){var a=m.info=NREUM.info,b=m.proto="https"===l.split(":")[0]||a.sslForHttp?"https://":"http://";if(a&&a.agent&&a.licenseKey&&a.applicationID){f("mark",["onload",e()]);var c=h.createElement("script");c.src=b+a.agent,h.body.appendChild(c)}}function d(){"complete"===h.readyState&&f("mark",["domContent",e()])}function e(){return(new Date).getTime()}var f=a("handle"),g=window,h=g.document,i="readystatechange",j="addEventListener",k="attachEvent",l=(""+location).split("?")[0],m=b.exports={offset:e(),origin:l};h[j]?(h[j](i,d,!1),g[j]("load",c,!1)):(h[k]("on"+i,d),g[k]("onload",c)),f("mark",["firstbyte",e()])},{handle:"4O2Y62"}],loader:[function(a,b){b.exports=a("YLUGVp")},{}]},{},["YLUGVp"]);</script>
<title>
Stengel v. Medtronic Inc., 676 F.3d 1159 (9th Cir. 2012), Court Opinion - Bloomberg Law 

</title>
<meta content='NOINDEX, NOFOLLOW' name='ROBOTS'>
<meta content='telephone=no' name='format-detection'>
<meta content='BLAW' name='apple-mobile-web-app-title'>
<meta name="csrf-param" content="authenticity_token"/>
<meta name="csrf-token" content="NiJ+70&#47;qv61N1TFnbttr4ZzRa7IGhB5DMvou0CKGUXA="/>
<script src="/min_assets/framework.js?1389213936" type="text/javascript"></script>

<script src="/javascripts/daterange.js?1380743058" type="text/javascript"></script>
<script src="/javascripts/document/document.js?1382459272" type="text/javascript"></script>
<script src="/javascripts/document/document_viewer.js?1383685414" type="text/javascript"></script>
<script src="/javascripts/document/bciteutils.js?1388683076" type="text/javascript"></script>
<script src="/javascripts/jquery/jquery.query.js?1342203941" type="text/javascript"></script>
<script src="/javascripts/browser/browser.js?1387565892" type="text/javascript"></script>
<script src="/javascripts/document/image_viewer.js?1366129555" type="text/javascript"></script>
<script src="/javascripts/jquery/jquery.selection.js?1375450295" type="text/javascript"></script>
<script src="/javascripts/jquery/jquery.bb-copywithcitation.js?1383771008" type="text/javascript"></script>
<script src="/javascripts/document/copy_with_cite.js?1382560939" type="text/javascript"></script>
<script src="/javascripts/document/notepad.js?1366310522" type="text/javascript"></script>

<link href="/stylesheets/yui2/yui2_combo.css?1288273584" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/document_v2.css?1391022004" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/min_assets/framework.css?1391022047" media="screen,print" rel="stylesheet" type="text/css" />
<!--[if IE]>
<link href="/stylesheets/ie.css?1391022010" media="screen,print" rel="stylesheet" type="text/css" />
<![endif]-->
<link href="/stylesheets/search/search_results.css?1391022036" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/document.css?1391022003" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/document_viewer.css?1391022005" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/search/tree_view.css?1391022037" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/browser/browser_enhanced.css?1391021984" media="print,screen" rel="stylesheet" type="text/css" />
<style type='text/css'>
#content_document, #content_document h1, #content_document h2, #content_document h3, #content_document h4, #content_document h5, #content_document h6 { font-family:Times New Roman, Times, serif; }
				#content_document pre {
				white-space: pre-wrap;
				white-space: -moz-pre-wrap;
				white-space: -pre-wrap;
				white-space: -o-pre-wrap;
				word-wrap: break-word;
				font-family: Bloomberg Fixed 2 Unicode;
			}
			
			#content_document .page_no { 
				font-weight:bold;
				text-decoration:none;
			}
			
			#content_document .highlight { 
				font-weight:bold; 
				background-color:yellow; 
				color:black;
			}
			
			#content_document .bcitehi { 
				font-weight:bold; 
				background-color:violet; 
				color:black;
			}
			
			/*.UNICODE {
			}
			
			#content_document blockquote {
			}
			
			#content_document em {
			}   
			
			#content_document .tableofcontents {
			}
			
			#content_document div.blockgroup {
			}
			
			#content_document p.opinion_text {
			}  */
			
			#content_document, #content_document h1, #content_document h2, #content_document h3, #content_document h4, #content_document h5, #content_document h6, #content_document p, #content_document li, #content_document td, #content_document th, #content_document div {
				font-size: 11pt;
			}
			
			#content_document .main {
				text-align:center; 
				font-weight:bold; 
				color:black;
			}
			
			#content_document .ftnote { 
				font-style:italic;
			}
			
			#content_document .headline {
				font-weight:bold; 
				color:black;
			} 
			
			#content_document p.group{
				padding-top: 0; 
				padding-bottom: 1px; 
				padding-left: 0; 
				padding-right: 0;
				margin-top: 0; 
				margin-bottom: 1px; 
				margin-left: 0; 
				margin-right: 0;
			}
			
			#content_document .big {
				font-size: 13pt;
			}
			
			#content_document .indent {
				text-indent:2.5em;
			}
			
			#content_document .level2 {
				margin-left:2.5em;
				margin-right:2.5em;
			} 
			
			#content_document .level3 {
				margin-left:5em;
				margin-right:5em;
			} 					
			
			#content_document .level4 {
				margin-left:7.5em;
				margin-right:7.5em;
			} 					
			
			#content_document .level5 {
				margin-left:10em;
				margin-right:10em;
			} 					
			
			#content_document .level6 {
				margin-left:12.5em;
			} 					
			
			#content_document a.sup {
				font-size: 6pt; 
				vertical-align: top;
			}
			
			#content_document a.sup1 {
				font-size: 8pt; 
				vertical-align: top;
			}
			
			#content_document em.italic {
				font-style: italic;
			}
			
			#content_document em.bold {
				font-weight: bold;
				font-style: normal;
			}
			
			#content_document em.bold-big {
				font-size: 13pt; 
				font-weight: bold;
			}
			
			#content_document em.underline {
				font-style:normal; 
				text-decoration: underline;
			}
			
			#content_document em.bold-ital {
				font-weight: bold; 
				font-style: italic;
			}
			
			#content_document em.bold-underline {
				font-weight: bold; 
				text-decoration: underline;
			}
			
			#content_document em.ital-underline {
				font-style: italic; 
				text-decoration: underline;
			}
			
			#content_document em.ital-bold-underline { 
				font-style: italic; 
				font-weight: bold; 
				text-decoration: underline;
			}
			
			#content_document em.small-cap {
				font-style:normal; 
				font-variant: small-caps;
			}
			
			#content_document em.strike {
				font-style: normal;
				text-decoration: line-through;
			}
			
			#content_document .small-cap {
				font-style:normal; 
				font-variant: small-caps;
			}
			
			#content_document h1.organization {
				font-weight: bold; 
				text-align:center; 
				font-style: normal;
			} 
			
			#content_document h2.organization {
				font-weight: bold; 
				text-align:left;
				margin-left:2.5em; 
				margin-right:2.5em;
			}
			
			#content_document h3.organization {
				font-weight: bold; 
				text-align:left;
				margin-left:5em; 
				margin-right:5em;
			}
			
			#content_document h4.organization {
				font-weight: bold;
				text-align:left;
				margin-left:7.5em; 
				margin-right:5em;
			}
			
			#content_document h5.organization {
				font-weight: bold; 
				text-align:left;
				margin-left:10em; 
				margin-right:5em;
			}
			
			#content_document h2.citation {
				font-weight: bold; 
				text-align:left;
			}
			
			#content_document div.blcitation {
				font-size: 7pt; 
				text-align:center;
			}
			
			#content_document .italic {
				font-style:italic;
			}	
			
			#content_document ul.dash {
				list-style-type: none;
			}
			
			#content_document ul.bullet {
				list-style-type: disc;
			}
			
			#content_document ul.none {
				list-style-type: none;
			}
			
			#content_document li.off {
				list-style-type: none; 
			}
			
			#content_document .mypre { 
				font-size: 100%;
			}
			
			#content_document .TOC {
				text-align:left;  
				padding:5px;  
				margin:0 auto;  
				color: #000000;  
				font-weight: 500;
			}
			
			#content_document .TOC hr { 
				color:#339999;  
				background-color:#339999;  
				width:100%;  
				clear: both;  
				border: none;
			}
			
			#content_document .bluehr { 
				color:#339999;  
				background-color:#339999;  
				width:100%;  
				clear: both;  
				border: none;
			}
			
			#content_document .headinga { 
				color: #339999;   
				font-size: 20px;
				font-weight: 500;
				text-align: center;
			}
			
			#content_document .tocentry {
				text-indent:-18px;
				padding-left:18px;
				color: #003399;
				font-weight: 700;
			}
			
			#content_document .doctext {  
				margin:0 auto;  
				text-align: left;  
			}				 
			
			#content_document span.PAGE { 
				color: black; 
				font-weight: bold 
			}
			
			#content_document a:link {  	
				color: #003399;  
				font-weight: 700;
			}
			
			#content_document a:visited {  
				color: #660066;   
				font-weight: 700;
			}
			
			#content_document .fn{  
				padding-left: 50 px; 
				font-weight: 550;
			}				
			
			#content_document .fr a:link {  
				color: #003399;  
				font-weight: 600;
			}
			
			#content_document .fr a:visited {  
				color: #660066;  
				font-weight: 600;
			}
			
			#content_document .headinga { 
				color: #339999;   
				font-size: 20px;
				font-weight: 600;
				text-align: center;
			}
			
			#content_document .volume {  
				text-align:center;  
				padding:5px;  
				margin:0 auto;  
				color: #000000;  
				font-weight: 500;
			}				
			
			#content_document h2.blcitation {
				font-size: 7pt; 
				text-align:center; 
				white-space:nowrap;
			}
			
			#content_document cite.blcitation {
				white-space:nowrap;
			}
			
			#content_document table.page_legend { 
					width: 100px; 
					text-align: left; 
					background-color: white; 
					font-family: Bloomberg Proportional Unicode;
					font-size: 12px
			}
			#content_document div.page_text {  padding-left: 50 px; margin:0 0 0 50px;  text-align: center;  width:100px; font-size: 12px}

			#content_document .smalllinks{  text-align: right;  font-size: 10px;  font-weight: 500;}		
			
			#content_document .opinion_headnotes{
				margin-top:6px;
				margin-bottom:6px;
			}
			
			#content_document .headnote_group{
				padding: 10px 10px 2px 10px;
				background-color: #ECECEC;
				margin-top:4px;
				margin-bottom:10px;
			}
			
			#content_document .headnote_group_header{
				font-weight: bold;
				margin-bottom: 8px;
			}
			
			#content_document .opinion_headnote{
				clear:both;
				padding-bottom: 4px;
				margin-bottom:10px;
			}
			
			#content_document .highlighted_headnote{
				background-color: #FFFF22;
			}
			
			#content_document .headnote_link{
				font-weight:bold;
				text-decoration: none;
			}
			
			#content_document .show_hide_headnotes{
			}
			
			#content_document .clearfix:after {
				clear:both;
				content: ".";
				height:0px;
				display:block;
				visibility:hidden;
			}
			
			/* BNA Headnotes */
			
			#content_document .headnotesContainer {
				margin: 12px 0;
				padding: 12px 0;
				border-top: 1px solid #000;
				border-bottom: 1px solid #000;
			}
			
			#content_document .headnotesContainer .headnotesContainerTitle {
				font-size: 16px;
				font-weight: bold;
				text-align: center;
			}
			
			#content_document .headnotesContainer .headnoteTitle {
				padding: 8px 12px;
				background-color: #dedede;
				margin: 24px 0 0 0;
				font-size: 16px;
				font-weight: bold;
				text-transform: uppercase;
			}
			
			#content_document .headnotesContainer .headnote {
				margin-left: 24px;
			}
			
			#content_document .headnotesContainer .headnote .headnoteSlug {
				margin-top: 12px;
				font-size: 16px;
				font-weight: bold;
			}
			
			#content_document .headnotesContainer .headnote .headnoteDescriptor {
				margin-top: 12px;
				font-weight: bold;
			}
			
			#content_document .headnotesContainer .headnote .headnoteToggle .headnoteText {
				margin-bottom: 12px;
			}
		
</style>
<link href="/stylesheets/yui_calendar.css?1391022047" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/docviewer_overrides.css?1391022005" media="print,screen" rel="stylesheet" type="text/css" />

<link href="/stylesheets/print.css?1391022029" media="print" rel="stylesheet" type="text/css" />
<link href='/images/favicon.ico' rel='shortcut icon'>
</head>
<body class='securities  document '>
<div class='container'>
<div id='page_loader'></div>
<div class='printHeader printOnly'>
<img src='/images/print_header.jpg'>
<div class='user'>
<span>
Prepared for: Susan Yeh
</span>
</div>
</div>
<div class='topBarHolder printHide'>
<div class='topBar'>
<ul class='topBarElements'>
<li class='skip'>
<a href="#primary_content" tabindex="1">Skip Navigation</a>
</li>
<li class='logout'>
<a href="/log_out.htm" id="logoutButton" onclick="generateExplicitLogoutEvent();">Logout</a>
</li>
<li id='help'>
<a href="/help" target="_blank">Help</a>

</li>
<li id='user'>
<a href="/settings">Susan Yeh</a>

</li>
<li class='withNotifications' id='client_matter'>
<div class='clientMatterDropDown'>
<div>Client Matter</div>
<div class='skinButton blueAlert' style='display:none'>
<span id='currentClientMatter'>

</span>
</div>
<span class='noneSelected' style=''>
&nbsp;(None Selected)
</span>
<div class='expandable'></div>
</div>
<div class='topNavDropdown' id='sub_client_matter'>
<ul>
<li style='display:none'>
<a class='remove_client_matter_menu_item' href='#' onclick='return true;' title='Remove Current Client Matter'>
Remove Current Client Matter
</a>
</li>
<li>
<a class='enter_client_matter_menu_item' href='#' onclick='return true;' title='Enter Client Matter'>
Enter Client Matter
</a>
</li>
</ul>
</div>

</li>
<li class='withNotifications' id='alerts'>
<a href="/alerts/inbox"><div id='unreadAlertsCount'>
Saved Searches & Alerts
</div>
</a>
</li>
<li class='withNotifications' id='downloads'>
<a href="/download/download_center"><div id='unreadDownloadsCount'>
<div>Downloads</div>
</div>
</a>
</li>
<li id='research_trail'>
<a href="/research_trail"><div>Research Trail</div>
</a>
</li>
<li id='workspaces'>
<a href="/workspaces"><div>Workspaces</div>

</a></li>
</ul>
</div>
</div>

<div class='topMenu textBkDark printHide' id='top_menu'>
<div class='contextHolder'>
<a href='/home'>
<h1 class='logo'></h1>
</a>
<div class='menuRow'>
<ul class='menuItems'>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_HOME' onclick="javascript:navigation_selectMenuItem('HOME');">
Home
</a>
</li>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button active' id='nav_menu_button_search' onclick="javascript:navigation_selectMenuItem('search');">
Search & Browse
</a>
</li>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_practice_areas' onclick="javascript:navigation_selectMenuItem('practice_areas');">
Practice Centers
</a>
</li>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_LITIGATION' onclick="javascript:navigation_selectMenuItem('LITIGATION');">
Litigation & Dockets
</a>
</li>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_transactional' onclick="javascript:navigation_selectMenuItem('transactional');">
Transactional Law
</a>
</li>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_LEG_REG' onclick="javascript:navigation_selectMenuItem('LEG_REG');">
Legislative & Regulatory
</a>
</li>
<li class='legalAnalysis' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_news' onclick="javascript:navigation_selectMenuItem('news');">
Legal Analysis & News
</a>
</li>
<li class='last' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_market' onclick="javascript:navigation_selectMenuItem('market');">
Companies & Markets
</a>
</li>

</ul>
</div>
<form accept-charset="UTF-8" action="/autocomplete/jump" id="search_form" method="post"><div style="margin:0;padding:0;display:inline"><input name="utf8" type="hidden" value="&#x2713;" /><input name="authenticity_token" type="hidden" value="NiJ+70/qv61N1TFnbttr4ZzRa7IGhB5DMvou0CKGUXA=" /></div>
<input id='quicksearch_context' name='context_value' type='hidden' value='PRACTICE'>
<div class='searchBox' id='quick_search'>
<div class='inputContainer'>
<input autocomplete='off' id='quick_search_term' name='term' onkeydown='framework_handleTextInput(event,quick_search_term)' tabindex='2' type='text'>
<div class='searchButton' onmouseup='return framework_activateForm();' tabindex='3'></div>
<a href="/help/BLAWHelpSystem.htm#GO_Using_the_GO_BAR.htm" class="infoBtn" target="_blank" title="Using the &lt;GO&gt; Bar"></a>
<input id='quick_search_post' name='qs_type' type='hidden' value='general'>
<input id='quick_search_type' name='type' type='hidden' value='input_terms'>
<input id='quick_search_value' name='item_value' type='hidden'>
<input id='quick_search_origin' name='search_type' type='hidden' value='LAW'>
</div>
</div>
</form>


</div>
</div>

<div class='main clearfix'>
<div class='menuDrawer'>
<div class='interior'>
<div class='drawer_shade drawerShade clearfix'>
<div class='dropShadow'></div>
<div class='sub_menu subMenu' id='sub_menu_HOME'>
<table>
<tr>
<td class=''>
<ul>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_search'>
<div class='subTitles'>
<div class='subItem one '>
Search
</div>
<div class='subItem two '>
Specialized Searches
</div>
<div class='subItem one last'>
Browse
</div>
<div class='clearfix'></div>
</div>
<table>
<tr>
<td class=''>
<ul>
<li class='last'>
<a class='clearfix' href='/legal_search'>
<div class='navLinkTitle'>
All Legal Content
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/company_search'>
<div class='navLinkTitle'>
Company Screener
</div>
</a>
</li>
<li>
<a class='clearfix' href='/opinion_search'>
<div class='navLinkTitle'>
Court Opinions
</div>
</a>
</li>
<li>
<a class='clearfix' href='/dealmaker_document_search'>
<div class='navLinkTitle'>
DealMaker Documents
</div>
</a>
</li>
<li>
<a class='clearfix' href='/dockets'>
<div class='navLinkTitle'>
Dockets
</div>
</a>
</li>
<li>
<a class='clearfix' href='/dnds_search'>
<div class='navLinkTitle'>
Domain Name Decisions
</div>
</a>
</li>
<li>
<a class='clearfix' href='/edgar_search'>
<div class='navLinkTitle'>
EDGAR
</div>
</a>
</li>
<li>
<a class='clearfix' href='/clthreads/company-search-clc.php' target='_blank'>
<div class='navLinkTitle'>
EDGAR Comment Threads
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/leg_search'>
<div class='navLinkTitle'>
Legislative
</div>
</a>
</li>
<li>
<a class='clearfix' href='/news/advanced_search'>
<div class='navLinkTitle'>
News
</div>
</a>
</li>
<li>
<a class='clearfix' href='/patent_search'>
<div class='navLinkTitle'>
Patents
</div>
</a>
</li>
<li>
<a class='clearfix' href='/people_search'>
<div class='navLinkTitle'>
People
</div>
</a>
</li>
<li>
<a class='clearfix' href='/reg_search'>
<div class='navLinkTitle'>
Regulatory
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/no_action_search'>
<div class='navLinkTitle'>
SEC No-Action Letters
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/law_reports'>
<div class='navLinkTitle'>
BNA Law Reports
</div>
</a>
</li>
<li>
<a class='clearfix' href='/nav_content_menu/105.456024'>
<div class='navLinkTitle'>
BNA Manuals
</div>
</a>
</li>
<li>
<a class='clearfix' href='/nav_content_menu/105.456026'>
<div class='navLinkTitle'>
BNA Portfolios
</div>
</a>
</li>
<li>
<a class='clearfix' href='/nav_content_menu/105.102923'>
<div class='navLinkTitle'>
Books & Treatises
</div>
</a>
</li>
<li>
<a class='clearfix' href='/nav_content_menu/105.293113'>
<div class='navLinkTitle'>
Federal Law
</div>
</a>
</li>
<li>
<a class='clearfix' href='/map_nav/laws_regs'>
<div class='navLinkTitle'>
State Law
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_practice_areas'>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/antitrust'>
<div class='navLinkTitle'>
Antitrust
</div>
</a>
</li>
<li>
<a class='clearfix' href='/banking_finance'>
<div class='navLinkTitle'>
Banking & Finance
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/bankruptcy'>
<div class='navLinkTitle'>
Bankruptcy
</div>
</a>
</li>
</ul>
</td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/corporate_ma'>
<div class='navLinkTitle'>
Corporate/M&A
</div>
</a>
</li>
<li>
<a class='clearfix' href='/employee_benefits'>
<div class='navLinkTitle'>
Employee Benefits
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/health'>
<div class='navLinkTitle'>
Health
</div>
</a>
</li>
</ul>
</td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/ip_law'>
<div class='navLinkTitle'>
Intellectual Property
</div>
</a>
</li>
<li>
<a class='clearfix' href='/labor_employment'>
<div class='navLinkTitle'>
Labor & Employment
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/securities'>
<div class='navLinkTitle'>
Securities
</div>
</a>
</li>
<li>
<a class='clearfix' href='/tax'>
<div class='navLinkTitle'>
Tax
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_LITIGATION'>
<div class='subTitles'>
<div class='subItem two '>
Litigation
</div>
<div class='subItem two last'>
Dockets
</div>
<div class='clearfix'></div>
</div>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/opinion_search'>
<div class='navLinkTitle'>
Search Court Opinions
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/nav_menu/X7TO28O'>
<div class='navLinkTitle'>
BNA Outlines & Headnotes
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/nav_content_menu/105.103000'>
<div class='navLinkTitle'>
Federal Rules
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/general'>
<div class='navLinkTitle'>
Litigation Resources
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/dockets'>
<div class='navLinkTitle'>
Search Dockets
</div>
</a>
</li>
<li>
<a class='clearfix' href='/dockets/breaking'>
<div class='navLinkTitle'>
Breaking Complaints
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/dockets/analytics'>
<div class='navLinkTitle'>
Docket Analytics
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/dockets/coverage'>
<div class='navLinkTitle'>
Docket Coverage
</div>
</a>
</li>
<li>
<a class='clearfix' href='/dockets/requests'>
<div class='navLinkTitle'>
Docket Requests
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/dockets/tracking'>
<div class='navLinkTitle'>
Docket Tracking
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_transactional'>
<div class='subTitles'>
<div class='subItem two '>
Search
</div>
<div class='subItem two last'>
Resources
</div>
<div class='clearfix'></div>
</div>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/edgar_search'>
<div class='navLinkTitle'>
EDGAR
</div>
</a>
</li>
<li>
<a class='clearfix' href='/clthreads/company-search-clc.php' target='_blank'>
<div class='navLinkTitle'>
EDGAR Comment Threads
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/example_and_saved_searches'>
<div class='navLinkTitle'>
Example Searches
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/dealmaker_document_search'>
<div class='navLinkTitle'>
DealMaker Documents
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/dealmaker_clause_search'>
<div class='navLinkTitle'>
DealMaker Clauses
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/deal_maker/current_awareness'>
<div class='navLinkTitle'>
Current Awareness
</div>
</a>
</li>
<li>
<a class='clearfix' href='/nav_menu/X7TS80O'>
<div class='navLinkTitle'>
Drafting Guides & Overviews
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/nav_menu/X7TVS0O'>
<div class='navLinkTitle'>
Transactional Legal Treatises
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/deal_maker/resources'>
<div class='navLinkTitle'>
Transactional Resources
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_LEG_REG'>
<div class='subTitles'>
<div class='subItem two '>
Legislative
</div>
<div class='subItem two last'>
Regulatory
</div>
<div class='clearfix'></div>
</div>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/leg_search'>
<div class='navLinkTitle'>
Search Legislative
</div>
</a>
</li>
<li>
<a class='clearfix' href='/leg_search/congressional_bill_search'>
<div class='navLinkTitle'>
Search Congressional Bills
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/nav_browser/105.24221'>
<div class='navLinkTitle'>
U.S. Code
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/map_nav/laws_regs'>
<div class='navLinkTitle'>
State Legislative Materials
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/leg_news_analysis'>
<div class='navLinkTitle'>
Legislative Resources
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/reg_search'>
<div class='navLinkTitle'>
Search Regulatory
</div>
</a>
</li>
<li>
<a class='clearfix' href='/reg_search/federal_register_search'>
<div class='navLinkTitle'>
Search Federal Register
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/nav_browser/105.24230'>
<div class='navLinkTitle'>
Code of Federal Regulations
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/map_nav/laws_regs'>
<div class='navLinkTitle'>
State Regulatory Materials
</div>
</a>
</li>
<li>
<a class='clearfix' href='/reg_updates'>
<div class='navLinkTitle'>
Monitor Regulators
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/reg_news_analysis'>
<div class='navLinkTitle'>
Regulatory Resources
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_news'>
<div class='subTitles'>
<div class='subItem two '>
Legal Analysis
</div>
<div class='subItem two last'>
News
</div>
<div class='clearfix'></div>
</div>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/law_reports'>
<div class='navLinkTitle'>
BNA Law Reports
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/nav_content_menu/105.456024'>
<div class='navLinkTitle'>
BNA Manuals
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/nav_content_menu/105.456026'>
<div class='navLinkTitle'>
BNA Portfolios
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/nav_content_menu/105.102923'>
<div class='navLinkTitle'>
Books & Treatises
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/news/advanced_search'>
<div class='navLinkTitle'>
Search News
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/news'>
<div class='navLinkTitle'>
Legal News
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/news/topic'>
<div class='navLinkTitle'>
News by Topic
</div>
</a>
</li>
<li>
<a class='clearfix' href='/news/top_news'>
<div class='navLinkTitle'>
TOP News
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_market'>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/business_development'>
<div class='navLinkTitle'>
Business Development Center
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/edgar_search'>
<div class='navLinkTitle'>
Search EDGAR
</div>
</a>
</li>
</ul>
</td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/company'>
<div class='navLinkTitle'>
Company Watchlist
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/company_search'>
<div class='navLinkTitle'>
Company Screener
</div>
</a>
</li>
</ul>
</td>
<td class='backgroundExtend'>
<ul>
<li class='last'>
<a class='clearfix' href='/report_writer'>
<div class='navLinkTitle'>
Company Report Writer
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li class='last'>
<a class='clearfix' href='/market'>
<div class='navLinkTitle'>
Market News
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>

</div>
</div>
<div class='bottomFlange'></div>
</div>
<div class='breadcrumbContainer printHide'>
<div class='breadHolder'>
<!-- .breadcrumb -->
<div class='breadcrumb' id='breadcrumb_0'>
Search & Browse
</div>

<div class='breadcrumbDivider'>
/
</div>
<!-- .breadcrumb -->
<div class='breadcrumb' id='breadcrumb_1'>
<a href='/conversion/resolve_search/55b1904f2846408357ee26266414a254'>
Court Opinions
</a>
</div>

<div class='breadcrumbDivider'>
/
</div>
<!-- .breadcrumb -->
<div class='breadcrumb' id='breadcrumb_2'>
<a href='/opinion_search/results/55b1904f2846408357ee26266414a254'>
Search Results
</a>
</div>

<div class='breadcrumbDivider'>
/
</div>
</div>
</div>

</div>
<div class='page clearfix'>
<div class='content' id='page_content'>
<div id='statusHolder'></div>
<a name='primary_content'></a>

<div class='breadCrumbTitleRow clearfix eight grid'>
<div class="icon citation positive" title="Positive"></div>
<div class='title left' title='Stengel v. Medtronic Inc., 676 F.3d 1159 (9th Cir. 2012), Court Opinion'>
Stengel v. Medtronic Inc., 676 F.3d 1159 (9th Cir. 2012), Court Opinion
</div>
</div>

<div class='metadata' style='display: none'>
<div class='documentTitle'>Stengel v. Medtronic Inc., 676 F.3d 1159 (9th Cir. 2012), Court Opinion</div>
<div class='docId'>X1HF6K0003</div>
<div class='docType'>OPINIONS</div>
<div class='case_name'>Stengel v. Medtronic Inc.</div>
<div class='displayCitation'>2012 BL 92098</div>
<div class='displayCitation'>676 F.3d 1159</div>
<div class='displayCitation'>bna a0d1q5f8v3</div>
<div class='displayCitation'>wkf9case:25939264</div>
</div>

<div class='search_outline_node_popup' style='display:none'>
<form accept-charset="UTF-8" action="/document/class_outline_search" id="search_document_node_form" method="post"><div style="margin:0;padding:0;display:inline"><input name="utf8" type="hidden" value="&#x2713;" /><input name="authenticity_token" type="hidden" value="NiJ+70/qv61N1TFnbttr4ZzRa7IGhB5DMvou0CKGUXA=" /></div>
<div class='clearfix popupTitle'>
<div class='close' onclick='closePopup()'></div>
<h2>Search</h2>
</div>
<p class='searchOver'>
Search over:
<span class='search_target_node'></span>
<input class="search_source_id" id="source_id" name="source_id" type="hidden" />
<input class="search_node_id" id="search_node_id" name="search_node_id" type="hidden" />
<input class="search_service_code" id="search_service_code" name="search_service_code" type="hidden" />
<input class="search_division" id="search_division" name="search_division" type="hidden" />
<input autocomplete="off" class="search_node_text" id="search_term" name="search_term" type="text" />
</p>
<div class='clearfix'></div>
<div class='popUpActions'>
<button class='bootstrap skinButton popup action right print' onclick='this.form.submit();'>
<span>
Search
</span>
</button>
<button class='bootstrap skinButton popup cancel right' onclick='closePopup();' type='button'>
<span>
Cancel
</span>
</button>
</div>
</form>

</div>
<div id='no_matching_keywords_popup' style='display:none'>
<div class='popupTitle clearfix'>
<div class='close' onclick='closePopup()'></div>
<h2>No Matches Found</h2>
</div>
<p>
Search term(s) not found.
</p>
<div class='popUpActions'>
<button class='bootstrap skinButton popup cancel right' onclick='closePopup();' type='button'>
<span>
Close
</span>
</button>
</div>
</div>
<div id='copyWithCitationPopupContents' style='display:none'>
<div class='popupTitle clearfix'>
<div class='close' onclick='closePopup()'></div>
<h2>Copy with Citation</h2>
</div>
<p>
Copy the text below to paste into your document.
</p>
<div class='clearfix'>
<div class='copyWithCitationScrollBox'>
<div class='copyWithCitationArea left'>
<div class='copyWithCitationText'></div>
<div class='copyWithCitationDocumentTitle'></div>
</div>
<div class='ie9compat left'>
<img alt="" src="/images/transparency.png?1296705112" width="1" />
</div>
</div>
</div>
<div class='copyWithCitationCheckBoxHolder'>
<input checked="checked" class="linkCitation" id="link_citation" name="link_citation" onclick="updateCopyWithCitationLinks()" type="checkbox" value="true" />
Link citations to Bloomberg Law
</div>
<div class='popUpActions'>
<button class='bootstrap skinButton popup action right' onclick='closePopup();' type='button'>
<span>
Close
</span>
</button>
</div>
</div>

<script type='text/javascript'>
  //<![CDATA[
    $('#page_content').addClass("invisible");
  //]]>
</script>
<input id="doc_id" name="doc_id" type="hidden" value="X1HF6K0003" />
<input id="hidden_document_title" name="hidden_document_title" type="hidden" value="Stengel v. Medtronic Inc., 676 F.3d 1159 (9th Cir. 2012), Court Opinion" />
<input id="hidden_case_name" name="hidden_case_name" type="hidden" value="Stengel v. Medtronic Inc." />
<input id="hidden_case_docket" name="hidden_case_docket" type="hidden" />
<div class='toolHolder'>
<form accept-charset="UTF-8" action="" id="downloadPopupLinkForm" method="post"><div style="margin:0;padding:0;display:inline"><input name="utf8" type="hidden" value="&#x2713;" /><input name="authenticity_token" type="hidden" value="NiJ+70/qv61N1TFnbttr4ZzRa7IGhB5DMvou0CKGUXA=" /></div><input id="pde_location_type" name="pde_location_type" type="hidden" value="DOCUMENT" /><input id="full_doc_path" name="full_doc_path" type="hidden" value="/s/opinion/55b1904f2846408357ee26266414a254/document/X1HF6K0003?search32=DPNLUQBDE1FN0Q3IC5PMASPT64TJMSRPDPNMSUBDECUJ2" /><input id="document_type" name="document_type" type="hidden" value="OPINIONS" /><input id="doc_id" name="doc_id" type="hidden" value="X1HF6K0003&amp;search32=DPNLUQBDE1FN0Q3IC5PMASPT64TJMSRPDPNMSUBDECUJ2" /><input id="artifact_id" name="artifact_id" type="hidden" value="X1HF6K0003" /><input id="title" name="title" type="hidden" value="Stengel v. Medtronic Inc., 676 F.3d 1159 (9th Cir. 2012), Court Opinion" /><input id="search32" name="search32" type="hidden" value="DPNLUQBDE1FN0Q3IC5PMASPT64TJMSRPDPNMSUBDECUJ2" /><input id="citation_analysis" name="citation_analysis" type="hidden" value="POSITIVE" /><input id="context_resource_id" name="context_resource_id" type="hidden" value="55b1904f2846408357ee26266414a254" /><input id="has_sidebar_info" name="has_sidebar_info" type="hidden" value="true" /><input id="tab_types_" name="tab_types[]" type="hidden" value="TAB_OPINION" /><input id="has_notepad" name="has_notepad" type="hidden" value="true" /><input id="notepad_id" name="notepad_id" type="hidden" value="X1HF6K0003" /><input id="has_headnotes" name="has_headnotes" type="hidden" value="false" /><input id="preselect_option" name="preselect_option" type="hidden" value="DOCUMENT" /></form>

<ul class='tools printHide'>
<li>
<a href="#" onclick="javascript:quickPrintLink(); return false;">Quick Print</a>

</li>
<li>
<a href="#" onclick="javascript:createFormPopupFromForm('download','downloadPopupLinkForm'); return false;">Print/Download</a>
</li>
<li>
<a href="#" onclick="javascript:createFormPopupFromForm('email','downloadPopupLinkForm'); return false;">Email</a>
</li>
<li>
<a href="#" onclick="javascript:addPopupForm('add_to_workspace','?resource_path=%2Fs%2Fopinion%2F%35%35b%31%39%30%34f%32%38%34%36%34%30%38%33%35%37ee%32%36%32%36%36%34%31%34a%32%35%34%2Fdocument%2FX%31HF%36K%30%30%30%33%3Fsearch%33%32%3DDPNLUQBDE%31FN%30Q%33IC%35PMASPT%36%34TJMSRPDPNMSUBDECUJ%32&amp;document_type=OPINIONS', null); return false;">+ Workspace</a>
</li>
<li>
<a onclick='javascript:PDETray_default.addSelection();'>
+ Queue
</a>
</li>
<li class='last'></li>
</ul>
</div>

<div class='bootstrap printHide tabs'>
<a class='borderTab activeTab' id='tab_DOCUMENT'>
Document
</a>

<a href="/s/opinion/55b1904f2846408357ee26266414a254/bcite/X1HF6K0003/history" class="borderTab inactiveTab" id="tab_HISTORY" onclick="docTabSpinner()">Direct History</a>

<a href="/s/opinion/55b1904f2846408357ee26266414a254/bcite/X1HF6K0003/analysis" class="borderTab inactiveTab" id="tab_ANALYSIS" onclick="docTabSpinner()">Case Analysis</a>

<a href="/s/opinion/55b1904f2846408357ee26266414a254/bcite/X1HF6K0003/toa" class="borderTab inactiveTab" id="tab_TOA" onclick="docTabSpinner()">Table of Authorities</a>

<a href="/s/opinion/55b1904f2846408357ee26266414a254/related_content/X1HF6K0003?search32=DPNLUQBDE1FN0Q3IC5PMASPT64TJMSRPDPNMSUBDECUJ2" class="borderTab inactiveTab" id="tab_CITING_DOCS" onclick="docTabSpinner()">Citing Documents</a>

<div class='showHide printHide'>
<div class='showHideSidebarArrow'>
<a class='bliderText' id='bliderLink'>
<span id='bliderText'>
Hide General Info & Notepad
</span>
<span id='notepadCountLabel'></span>
</a>
</div>
</div>

</div>

<!-- document -->
<script type='text/javascript'>
  //<![CDATA[
    var fluid_layout=false;
  //]]>
</script>

<!-- %table.markupContainment -->
<!-- %tbody -->
<!-- %tr -->
<!-- %td#markup_holder{:valign=>"top", :align=>"left"} -->
<div class='docHolder legal hasSearchTerms ' id='doc_holder'>
<div class='documentContent ' id='content_document'>


<script type="text/javascript">
					function Blaw__Citator()
					{
						window.location="bloomberg:bcite_url_prefix=/rest/documents/1699955605507";
					}
				</script><script type="text/javascript">
      var BLAW_TOTAL_KEYWORD = 0;
      var BLAW_CURRENT_KEYWORD = -1;
      var BLAW_LAST_COLOR = "yellow";
      var BLAW_ANCHOR_NAME = "blawkeyword";
      var BLAW_BASE_URL = document.location.href;

      function Blaw__changeCurElem(lastAnchor, newAnchor)
      {
        var baseUrl = Blaw__getBaseURL(document.location.href);
        document.location.href = baseUrl + "#" + newAnchor;
        var elem = document.getElementById(lastAnchor)[0];
        if (elem) {
          elem.style.backgroundColor = BLAW_LAST_COLOR;
        }
        elem = document.getElementById(newAnchor)[0];
        if (elem) {
          BLAW_LAST_COLOR = elem.style.backgroundColor;
          elem.style.backgroundColor = "orange";
        }
      }

      function Blaw__findNextKeyWord()
      {
        var looped = false;
        var lastAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        if (++BLAW_CURRENT_KEYWORD >= BLAW_TOTAL_KEYWORD) {
          BLAW_CURRENT_KEYWORD = 0;
        }

        // if index does not exist on page continue to inc until one does
        while(document.getElementById(BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD).length == 0 && BLAW_CURRENT_KEYWORD < BLAW_TOTAL_KEYWORD) {
            ++BLAW_CURRENT_KEYWORD;
            // wrap around search, once only
            if (BLAW_CURRENT_KEYWORD >= BLAW_TOTAL_KEYWORD && !looped) {
              BLAW_CURRENT_KEYWORD = 0;
              looped = true;
            }
        }
        var newAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        Blaw__changeCurElem(lastAnchor, newAnchor);
      }

      function Blaw__findPrevKeyWord()
      {
        var looped = false;
        var lastAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        if (--BLAW_CURRENT_KEYWORD < 0) {
          BLAW_CURRENT_KEYWORD = BLAW_TOTAL_KEYWORD - 1;
          looped = true;
        }

        // if index does not exist on page continue to decr until one does
        while(document.getElementById(BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD).length == 0 && BLAW_CURRENT_KEYWORD >= 0) {
          --BLAW_CURRENT_KEYWORD;
          // wrap around search, once only
          if (BLAW_CURRENT_KEYWORD < 0 && !looped) {
            BLAW_CURRENT_KEYWORD = BLAW_TOTAL_KEYWORD - 1;
            looped = true;
          }
        }
        var newAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        Blaw__changeCurElem(lastAnchor, newAnchor);
      }

      function Blaw__findNextFrom(indx)
      {
        var lastAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        BLAW_CURRENT_KEYWORD = indx;
        ++BLAW_CURRENT_KEYWORD;
        if (BLAW_CURRENT_KEYWORD >= BLAW_TOTAL_KEYWORD) {
          BLAW_CURRENT_KEYWORD = 0;
        }
        var newAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        Blaw__changeCurElem(lastAnchor, newAnchor);
      }

      function Blaw__getBaseURL(url)
      {
        var reg = new RegExp("(.+)#.+$");
        var ar = reg.exec(url);
        if (ar != null) {
          return ar[1];
        } else {
          return url;
        }
      }


    </script><div xmlns:fo="http://www.w3.org/1999/XSL/Format" class="metadata" style="display: none">
<div class="pagination_series_list">PrimaryFederalReporter,Bloomberg,</div>
<div class="citation-group">
<div class="cite" data-cite-type="PrimaryFederalReporter">676 F.3d 1159</div>
<div class="cite" data-cite-type="DocketNumber">10-17755</div>
<div class="cite" data-cite-type="Bloomberg">2012 BL 92098</div>
</div>
</div>
<div align="left" class="tableofcontents">
<br CLEAR="right"><div class="page_text" style="float:right">
<b>Pagination</b><table class="page_legend" cellspacing="0">
<tr>
<td width="25%" align="left" valign="top">*</td>
<td width="50%" align="left" valign="top">F.3d </td>
</tr>
<tr>
<td width="25%" align="left" valign="top">**</td>
<td width="50%" align="left" valign="top">BL</td>
</tr>
</table>
</div>
<br>
</div>
<table><tbody><tr><td>&nbsp;</td></tr></tbody></table>
<p><center>
United States Court of Appeals, Ninth Circuit.
</center></p>
<hr align="center" width="65%">
<p><center>
Richard STENGEL; Mary Lou Stengel, Plaintiffs-Appellants, v. MEDTRONIC
INCORPORATED, a foreign corporation, Defendant-Appellee.
</center></p>
<hr align="center" width="65%">
<p><center>
No. 10-17755.
</center></p>
<p><center>
Argued and Submitted January 13, 2012.
</center></p>
<p><center>
Filed April 16, 2012.
</center></p>
<span CLASS="page_no" data-cite="676 f 3d 1160" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1160" data-primary-citation="676 F.3d 1159">[*1160]</span> <div id="para2" printdualcolumn="true"><p>
  Thomas G. Cotter, Stanley G. Feldman, and Stephen T.
Portell; Haralson Miller, Pitt, Feldman &amp; McAnally, P.L.C.,
Tucson, AZ, for the plaintiffs-appellants.
</p></div>
<div id="para2" printdualcolumn="true"><p>
  Michael K. Brown, Ginger F.H. Pigott, and Lisa M. Baird, Reed
Smith LLP, Los Angeles, CA, for the defendant-appellee.
</p></div>
<div id="para2" printdualcolumn="true"><p>
  Appeal from the United States District Court for the
District of Arizona, Raner C. Collins, District Judge,
Presiding. D.C. No. 4:10-cv-00318-RCC.
</p></div>
<div id="para2" printdualcolumn="true"><p>
  Before: J. CLIFFORD WALLACE, JOHN T. NOONAN, and MILAN D.
SMITH, JR., Circuit Judges.
</p></div>
<div id="para2" printdualcolumn="true"><p>
  Opinion by Judge WALLACE; Dissent by Judge NOONAN.
</p></div>
<div id="contentOpinion" printdualcolumn="true"><div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
                                 <b>OPINION</b>
</p></div></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  WALLACE, Senior Circuit Judge:
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Richard and Mary Lou Stengel brought several state causes
of action in Arizona state court against Medtronic Incorporated
(Medtronic) for injuries sustained by Richard Stengel (Stengel)
from his use of a pain pump manufactured by Medtronic.
Medtronic timely removed the case to the United States District
Court for the District of Arizona. The district court dismissed
the Stengels' claims as preempted by federal law and the
Stengels appealed. We have jurisdiction under
<a href="/s/opinion/55b1904f2846408357ee26266414a254/document/XEIMU8003?jcsearch=28%20usc%201291&amp;summary=yes#jcite">28 U.S.C. &sect; 1291</a>. We affirm.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
                                   <b>I.</b>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Medtronic's pain pump is a medical device that infuses
prescription medication through a catheter into the intrathecal
space within the spine to help control severe pain. In 1988,
the Food and Drug Administration (FDA) gave premarket approval
as a Class III medical device for Medtronic's SynchroMed Pump
&amp; Infusion System. In 1999, the FDA gave supplemental
<span CLASS="page_no" data-cite="676 f 3d 1161" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1161" data-primary-citation="676 F.3d 1159">[*1161]</span> 
premarket approval for Medtronic's SynchroMed EL Pump and
intrathecal catheter, which are the versions of Medtronic's
device at issue in this action.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  In 2000, Stengel had a Medtronic pump surgically implanted in
his abdomen and began receiving medication through the catheter
tip implanted in his spine. In 2005, Stengel began experiencing
ascending paralysis in his lower extremities caused by a
granuloma (a type of inflammation) in his spine that had formed
at the tip of the catheter. Stengel's doctors surgically
removed the hardware and most of the granuloma, but not in time
to prevent the granuloma from rendering Stengel permanently
paraplegic.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The Stengels' complaint alleged four generic claims under
Arizona law: negligence, breaches of express and implied
warranties, and strict liability. The district court granted
Medtronic's motion to dismiss the complaint on the ground that
federal law expressly preempted these claims.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  While the motion to dismiss was pending, the Stengels moved for
leave to amend their complaint to re-allege the same four claims
under the newly-proffered theory that Stengel's injury was
caused by Medtronic's failure to implement procedures to
evaluate complaints about the pump and failure to report
information to the FDA, as was required by FDA regulations. The
Stengels alleged that if Medtronic had complied with <span CLASS="page_no" data-cite="2012 bl 92098 p 2" data-cite-type="Bloomberg" data-cite-pageno="2" data-primary-citation="">[**2]</span> the
regulations, Medtronic would have warned physicians about the
newly-discovered danger that the pump might cause inflammation,
which would have allowed a quicker diagnosis of Stengel's
symptoms and prevented his paralysis. The Stengels' motion for
leave to amend was denied on the ground that this
"failure-to-warn" claim was impliedly preempted.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  We review <i>de novo</i> the district court's holding that
all of the Stengels' asserted claims were either expressly or
impliedly preempted. <i>Martinez v. Wells Fargo Home Mortg.,</i>
<i>Inc.</i>, <a href="/s/opinion/55b1904f2846408357ee26266414a254/document/X1CQG1Q003?jcsearch=598%20f%203d%20549&amp;summary=yes#jcite">598 F.3d 549</a>, <a href="/s/opinion/55b1904f2846408357ee26266414a254/document/X1CQG1Q003?jcsearch=598%20f%203d%20549&amp;summary=yes#jcite">553</a> (9th Cir. 2010). We review its
denial of leave to amend for abuse of discretion. <i>Alvarez</i>
<i>v. Chevron Corp.</i>, <a href="/s/opinion/55b1904f2846408357ee26266414a254/document/X1G7T4E003?jcsearch=656%20f%203d%20925&amp;summary=yes#jcite">656 F.3d 925</a>, <a href="/s/opinion/55b1904f2846408357ee26266414a254/document/X1G7T4E003?jcsearch=656%20f%203d%20925&amp;summary=yes#jcite">931</a> (9th Cir. 2011).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
                                   <b>II.</b>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  In 1976, Congress amended the Food, Drug and Cosmetic Act
(FDCA) by enacting the Medical Device Amendments of 1976 (MDA),
Pub.L. No. <a href="/s/opinion/55b1904f2846408357ee26266414a254/document/1?citation=USACTS%2094-295&amp;summary=yes#jcite">94-295</a>, <a href="/s/opinion/55b1904f2846408357ee26266414a254/document/1?citation=90%20stat%20539&amp;summary=yes#jcite">90 Stat. 539</a> (codified as amended at
<a href="/s/opinion/55b1904f2846408357ee26266414a254/document/XEI5PI003?jcsearch=21%20usc%20360c&amp;summary=yes#jcite">21 U.S.C. &sect; 360c</a> <i>et seq.</i>). The MDA added a preemption
clause to the FDCA which provides, subject to limited
exceptions, that
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  no State . . . may establish . . . with respect to a
  device intended for human use any requirement &mdash;
  (1) which is different from, or in addition to, any
  requirement applicable under [the FDCA], and (2) which
  relates to the safety or effectiveness of the device
  or to any other matter included in a requirement
  applicable to the device under [the FDCA].
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<a href="/s/opinion/55b1904f2846408357ee26266414a254/document/XEI5Q2003?jcsearch=21%20U.S.C.%20%20360k(a)&amp;summary=yes#jcite">21 U.S.C. &sect; 360k</a>(a).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The Supreme Court has examined the extent to which this
preemption clause "bars common-law claims challenging the
safety and effectiveness of a medical device given premarket
approval by the [FDA]." <i>Riegel v. Medtronic, Inc.</i>,
<a href="/s/opinion/55b1904f2846408357ee26266414a254/document/X18HPKU003?jcsearch=552%20us%20312&amp;summary=yes#jcite">552 U.S. 312</a>, <a href="/s/opinion/55b1904f2846408357ee26266414a254/document/X18HPKU003?jcsearch=552%20us%20312&amp;summary=yes#jcite">315</a>, <a href="/s/opinion/55b1904f2846408357ee26266414a254/document/1?citation=128%20supreme%20court%20999&amp;summary=yes#jcite">128 S.Ct. 999</a>, <a href="/s/opinion/55b1904f2846408357ee26266414a254/document/X18HPKU003?jcsearch=169%20l%20ed%202d%20892&amp;summary=yes#jcite">169 L.Ed.2d 892</a> (2008). The Court
reviewed the "rigorous" premarket approval process for Class
<b>III</b> medical devices:
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  A manufacturer must submit what is typically a
  multivolume application. It includes, among other
  things, full reports of all studies and investigations
  of the device's safety and effectiveness that have
  been published or should reasonably
<span CLASS="page_no" data-cite="676 f 3d 1162" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1162" data-primary-citation="676 F.3d 1159">[*1162]</span> 
  be known to the applicant; a full statement of the
  device's components, ingredients, and properties and
  of the principle or principles of operation; a full
  description of the methods used in, and the facilities
  and controls used for, the manufacture, processing,
  and, when relevant, packing and installation of, such
  device; samples or device components required by the
  FDA; and a specimen of the proposed labeling. Before
  deciding whether to approve the application, the
  agency may refer it to a panel of outside experts and
  may request additional data from the manufacturer.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The FDA spends an average of 1,200 hours reviewing
  each application and grants premarket approval only if
  it finds there is a reasonable assurance of the
  device's safety and effectiveness.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<i>Id.</i> at 317-18, <a href="/s/opinion/55b1904f2846408357ee26266414a254/document/1?citation=128%20supreme%20court%20999&amp;summary=yes#jcite">128 S.Ct. 999</a> (internal citations and
quotation marks omitted).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The premarket approval process includes review of the device's
proposed labeling to evaluate safety and effectiveness under
the conditions of use set forth in the label. <i>Id.</i>
at 318, <a href="/s/opinion/55b1904f2846408357ee26266414a254/document/1?citation=128%20supreme%20court%20999&amp;summary=yes#jcite">128 S.Ct. 999</a>. After a device is approved, "the MDA
for-bids the manufacturer to make, without FDA permission,
changes in design specifications, manufacturing processes,
labeling, or any other attribute, that would affect safety or
effectiveness." <i><a href="/s/opinion/55b1904f2846408357ee26266414a254/document/X18HPKU003?jcsearch=552%20U.S.%20312&amp;summary=yes#jcite">Id</a>.</i> at 319, <a href="/s/opinion/55b1904f2846408357ee26266414a254/document/1?citation=128%20supreme%20court%20999&amp;summary=yes#jcite">128 S.Ct. 999</a>. Any changes
must be made <span CLASS="page_no" data-cite="2012 bl 92098 p 3" data-cite-type="Bloomberg" data-cite-pageno="3" data-primary-citation="">[**3]</span> after FDA approval of an application for
supplemental premarket approval, "to be evaluated under largely
the same criteria as an initial application." <i>Id.</i>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The Court then held that the premarket approval
process for Class III devices imposed federal "requirements"
applicable to the approved device, that common law tort duties
constituted state "requirements," and that the "safety and
effectiveness" of the device was the subject of the plaintiffs
common law claims. <i></i><a href="/s/opinion/55b1904f2846408357ee26266414a254/document/X18HPKU003?jcsearch=552%20U.S.%20312&amp;summary=yes#jcite">Id. at 322-23</a>, <a href="/s/opinion/55b1904f2846408357ee26266414a254/document/1?citation=128%20supreme%20court%20999&amp;summary=yes#jcite">128 S.Ct. 999</a>. The
Court recognized that section "360k does not prevent a State
from providing a damages remedy for claims premised on a
violation of FDA regulations" because "the state duties in such
a case `parallel,' rather than add to, federal requirements."
<i></i><a href="/s/opinion/55b1904f2846408357ee26266414a254/document/X18HPKU003?jcsearch=552%20U.S.%20312&amp;summary=yes#jcite">Id. at 330</a>, <a href="/s/opinion/55b1904f2846408357ee26266414a254/document/1?citation=128%20supreme%20court%20999&amp;summary=yes#jcite">128 S.Ct. 999</a>, <i>quoting Medtronic, Inc.</i>
<i>v. Lohr</i>, <a href="/s/opinion/55b1904f2846408357ee26266414a254/document/X5CCS2?jcsearch=518%20us%20470&amp;summary=yes#jcite">518 U.S. 470</a>, <a href="/s/opinion/55b1904f2846408357ee26266414a254/document/X5CCS2?jcsearch=518%20us%20470&amp;summary=yes#jcite">495</a>, <a href="/s/opinion/55b1904f2846408357ee26266414a254/document/1?citation=116%20supreme%20court%202240&amp;summary=yes#jcite">116 S.Ct. 2240</a>,
<a href="/s/opinion/55b1904f2846408357ee26266414a254/document/X5CCS2?jcsearch=135%20l%20ed%202d%20700&amp;summary=yes#jcite">135 L.Ed.2d 700</a> (1996). Because the plaintiff asserted that the defendant's
device "violated state tort law notwithstanding compliance with
the relevant federal requirements," the Court held their claims
to be expressly preempted. <i>Id.</i>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The Stengels' claims, as they appear in the initial complaint,
are expressly preempted under <a href="/s/opinion/55b1904f2846408357ee26266414a254/document/XEI5Q2003?jcsearch=21%20U.S.C.%20%20360k&amp;summary=yes#jcite">section 360k</a> and <i>Riegel.</i>
The claims generally challenged the safety and effectiveness of
Medtronic's pump without any hint of an allegation that
Medtronic's conduct violated FDA regulations. To be successful,
the claims would have required the trier of fact, as a matter
of state tort law, to conclude that the device should have
either been designed differently from what the FDA required
through premarket approval, or labeled with warnings different
from what the FDA required. Therefore, the district court
correctly dismissed the Stengels' initial complaint.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The claims alleged in Stengels' proposed amended complaint are
also expressly preempted to the extent they rely on the theory
that Medtronic should have sent a medical device correction
notice to physicians, whether or not the FDA ordered it,
because FDA regulations permitted Medtronic to send the notice
without prior FDA approval. <i>See</i>
<a href="/s/opinion/55b1904f2846408357ee26266414a254/document/XMJ9GA003?jcsearch=21%20C.F.R.%20%20814.39(d)&amp;summary=yes#jcite">21 C.F.R. &sect; 814.39</a>(d). The Seventh Circuit has addressed this precise
question. It held: "Where a federal requirement permits a
course of conduct and the state makes it obligatory, the
state's requirement is in addition to the
<span CLASS="page_no" data-cite="676 f 3d 1163" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1163" data-primary-citation="676 F.3d 1159">[*1163]</span> 
federal requirement and thus is preempted." <i>McMullen v.</i>
<i>Medtronic, Inc.</i>, <a href="/s/opinion/55b1904f2846408357ee26266414a254/document/X12NKIO003?jcsearch=421%20f%203d%20482&amp;summary=yes#jcite">421 F.3d 482</a>, <a href="/s/opinion/55b1904f2846408357ee26266414a254/document/X12NKIO003?jcsearch=421%20f%203d%20482&amp;summary=yes#jcite">489</a> (7th Cir. 2005). We
agree that such a requirement is expressly preempted.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
                                  <b>III.</b>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  However, portions of the claims in the Stengels' proposed
amended complaint could be interpreted to survive express
preemption. The proposed complaint alleged:
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Under federal law and regulation, [Medtronic] was
  under a continuing duty to monitor the product after
  premarket approval and to discover and report to the
  FDA any complaints about the product's performance and
  any adverse health consequences of which it became
  aware and that are or may be attributable to the
  product.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
Substitute Amended Complaint, &para; 13, ECF No. 22-1
(<i>citing</i> <a href="/s/opinion/55b1904f2846408357ee26266414a254/document/XEI5PU003?jcsearch=21%20usc%20360i&amp;summary=yes#jcite">21 U.S.C. &sect; 360i</a> (requirement to maintain
and submit information as required by regulation);
<a href="/s/opinion/55b1904f2846408357ee26266414a254/document/XMJ96I003?jcsearch=21%20cfr%20803%2050&amp;summary=yes#jcite">21 C.F.R. &sect; 803.50</a> (requirement to submit reports);
<a href="/s/opinion/55b1904f2846408357ee26266414a254/document/XMJ9KK003?jcsearch=21%20C.F.R.%20%20820.198(a)&amp;summary=yes#jcite">21 C.F.R. &sect; 820.198</a>(a) (requirement to establish procedures for reviewing
complaints)). Because <span CLASS="page_no" data-cite="2012 bl 92098 p 4" data-cite-type="Bloomberg" data-cite-pageno="4" data-primary-citation="">[**4]</span> of Medtronic's negligent failure to
perform these duties, the Stengels alleged, its pump became
defective and unfit for its intended purpose. <i></i><cite>Id.
&para; 20</cite>. To the extent Medtronic's alleged violations of FDA
regulations are actionable under state law, the state
obligations parallel the federal requirements, and thus are not
expressly preempted.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Nonetheless, this theory in the Stengels' amended complaint
which survives express preemption ultimately fails because the
claims are impliedly preempted under <i>Buckman Co. v.</i>
<i>Plaintiffs' Legal Committee</i>, <a href="/s/opinion/55b1904f2846408357ee26266414a254/document/X4U3HP?jcsearch=531%20us%20341&amp;summary=yes#jcite">531 U.S. 341</a>, <a href="/s/opinion/55b1904f2846408357ee26266414a254/document/1?citation=121%20supreme%20court%201012&amp;summary=yes#jcite">121 S.Ct. 1012</a>,
<a href="/s/opinion/55b1904f2846408357ee26266414a254/document/X4U3HP?jcsearch=148%20l%20ed%202d%20854&amp;summary=yes#jcite">148 L.Ed.2d 854</a> (2001). In <i>Buckman</i>, the plaintiffs
alleged that the defendant made fraudulent misrepresentations
to the FDA regarding the intended use of its bone screws and
that the devices were improperly given market clearance as a
result. <i><a href="/s/opinion/55b1904f2846408357ee26266414a254/document/X4U3HP?jcsearch=531%20U.S.%20341&amp;summary=yes#jcite">Id</a>.</i> at 346-47, <a href="/s/opinion/55b1904f2846408357ee26266414a254/document/1?citation=121%20supreme%20court%201012&amp;summary=yes#jcite">121 S.Ct. 1012</a>. The Supreme
Court held that the claims were preempted because, although the
defendant had allegedly violated federal requirements, allowing
the plaintiffs to bring a state cause of action to remedy the
injuries caused by the violations would interfere with the
congressional scheme. <i>Id.</i> As the Court explained, "the
federal statutory scheme amply empowers the FDA to punish and
deter fraud against the Administration, and . . this authority
is used by the Administration to achieve a somewhat delicate
balance of statutory objectives" which "can be skewed by
allowing fraud-on-the-FDA claims under state tort law."
<i></i><a href="/s/opinion/55b1904f2846408357ee26266414a254/document/X4U3HP?jcsearch=531%20U.S.%20341&amp;summary=yes#jcite">Id. at 348</a>, <a href="/s/opinion/55b1904f2846408357ee26266414a254/document/1?citation=121%20supreme%20court%201012&amp;summary=yes#jcite">121 S.Ct. 1012</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The Court observed that "[t]he FDCA leaves no doubt that it is
the Federal Government rather than private litigants who are
authorized to file suit for noncompliance with the medical
device provisions." <i></i><a href="/s/opinion/55b1904f2846408357ee26266414a254/document/X4U3HP?jcsearch=531%20U.S.%20341&amp;summary=yes#jcite">Id. at 349</a> n. 4, <a href="/s/opinion/55b1904f2846408357ee26266414a254/document/1?citation=121%20supreme%20court%201012&amp;summary=yes#jcite">121 S.Ct. 1012</a>,
<i>citing</i> <a href="/s/opinion/55b1904f2846408357ee26266414a254/document/XEI5N0003?jcsearch=21%20U.S.C.%20%20337(a)&amp;summary=yes#jcite">21 U.S.C. &sect; 337</a>(a) (no private right of
action to enforce FDCA). The Court held that "[s]tate-law
fraud-on-the FDA claims inevitably conflict with the FDA's
responsibility to police fraud consistently with the
Administration's judgment and objectives." <i>Id.</i> at 350,
<a href="/s/opinion/55b1904f2846408357ee26266414a254/document/1?citation=121%20supreme%20court%201012&amp;summary=yes#jcite">121 S.Ct. 1012</a>. The Court distinguished <i>Medtronic, Inc. v.</i>
<i>Lohr</i>, <a href="/s/opinion/55b1904f2846408357ee26266414a254/document/X5CCS2?jcsearch=518%20us%20470&amp;summary=yes#jcite">518 U.S. 470</a>, <a href="/s/opinion/55b1904f2846408357ee26266414a254/document/1?citation=116%20supreme%20court%202240&amp;summary=yes#jcite">116 S.Ct. 2240</a>, <a href="/s/opinion/55b1904f2846408357ee26266414a254/document/X5CCS2?jcsearch=135%20l%20ed%202d%20700&amp;summary=yes#jcite">135 L.Ed.2d 700</a>
(1996), in which the Court previously held certain negligence
claims not to be expressly preempted under the FDCA.
<a href="/s/opinion/55b1904f2846408357ee26266414a254/document/X4U3HP?jcsearch=531%20us%20341&amp;summary=yes#jcite">531 U.S. at 352-53</a>, <a href="/s/opinion/55b1904f2846408357ee26266414a254/document/1?citation=121%20supreme%20court%201012&amp;summary=yes#jcite">121 S.Ct. 1012</a>. It reasoned that "the
[<i>Lohr</i>] claims arose from the manufacturer's alleged
failure to use reasonable care in the production of the
product, not solely from the violation of FDCA requirements,"
whereas the <i>Buckman</i> fraud claims "exist solely by
virtue
<span CLASS="page_no" data-cite="676 f 3d 1164" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1164" data-primary-citation="676 F.3d 1159">[*1164]</span> 
of the FDCA disclosure requirements."
<a href="/s/opinion/55b1904f2846408357ee26266414a254/document/X4U3HP?jcsearch=531%20us%20341&amp;summary=yes#jcite">531 U.S. at 352-53</a>, <a href="/s/opinion/55b1904f2846408357ee26266414a254/document/1?citation=121%20supreme%20court%201012&amp;summary=yes#jcite">121 S.Ct. 1012</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  There is no meaningful distinction between the Stengels'
failure-to-warn claims and the "fraud-on-the-FDA" claims held
to be preempted in <i>Buckman.</i> Therefore, following
<i>Buckman</i>, we hold that the Stengels' claims are
impliedly preempted.<a HREF="#fn100" name="fnref_fn100">[fn1]</a> The Stengels' theory is that if
Medtronic had acted with reasonable care in complying with the
regulations that required it to provide information to the FDA,
the FDA would have required Medtronic to warn physicians about
the danger of inflammation connected to its pump and Stengel
could have avoided the injury caused by the pump. <i>See</i>
<a href="/s/opinion/55b1904f2846408357ee26266414a254/document/XEI5PS003?jcsearch=21%20U.S.C.%20%20360h(a)&amp;summary=yes#jcite">21 U.S.C. &sect; 360h</a>(a). This is precisely the same theory that
was rejected in <i>Buckman.</i> The only difference is that,
in <i>Buckman</i>, the defendant allegedly misinformed the
FDA overtly <span CLASS="page_no" data-cite="2012 bl 92098 p 5" data-cite-type="Bloomberg" data-cite-pageno="5" data-primary-citation="">[**5]</span> by providing false information, whereas here the
defendant allegedly misinformed the FDA tacitly by failing to
report information that it had a duty to report. The policing
of such conduct in both instances is committed exclusively to
the federal government, and recognizing a state cause of action
based on such conduct would conflict with the statutory scheme
established by Congress. <i>Cf. Cupek v. Medtronic, Inc.</i>,
<a href="/s/opinion/55b1904f2846408357ee26266414a254/document/X124CKA003?jcsearch=405%20f%203d%20421&amp;summary=yes#jcite">405 F.3d 421</a>, <a href="/s/opinion/55b1904f2846408357ee26266414a254/document/X124CKA003?jcsearch=405%20f%203d%20421&amp;summary=yes#jcite">423-24</a> (6th Cir. 2005) (negligence per se claim
due to "failure to comply with [FDA] conditions of approval"
preempted because it was a "disguised fraud on the FDA claim").
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The federal regulations that Medtronic is alleged to have
violated impose detailed reporting requirements with respect to
a broad category of information. For example, a manufacturer
must report to the FDA information the manufacturer becomes
aware of, from any source, that reasonably suggests that its
device may have caused or contributed to a serious injury.
<a href="/s/opinion/55b1904f2846408357ee26266414a254/document/XMJ96I003?jcsearch=21%20cfr%20803%2050&amp;summary=yes#jcite">21 C.F.R. &sect; 803.50</a>. This report must be made no later than 30
days after the day the manufacturer receives or becomes aware
of the information. <a href="/s/opinion/55b1904f2846408357ee26266414a254/document/XMJ96I003?jcsearch=21%20C.F.R.%20%20803.50(a)&amp;summary=yes#jcite">Section 803.50(a)</a>. The FDA considers
information that is reasonably known to the manufacturer to
include any information that the manufacturer can obtain by
contacting the initial reporter or by testing the device.
<a href="/s/opinion/55b1904f2846408357ee26266414a254/document/XMJ96I003?jcsearch=21%20C.F.R.%20%20803.50(b)&amp;summary=yes#jcite">Section 803.50(b)</a>. A manufacturer must investigate each adverse
event and evaluate the cause of the event.
<a href="/s/opinion/55b1904f2846408357ee26266414a254/document/XMJ96I003?jcsearch=21%20C.F.R.%20%20803.50(b)(3)&amp;summary=yes#jcite">Section 803.50(b)</a>(3). If the manufacturer cannot submit complete
information in a report, it must provide a statement explaining
why the information was incomplete and the steps taken to
obtain the information. <i><a href="/s/opinion/55b1904f2846408357ee26266414a254/document/XMJ96I003?jcsearch=21%20C.F.R.%20%20803.50(b)(3)&amp;summary=yes#jcite">Id</a>.</i> Regulations also require a
manufacturer to maintain complaint files and establish
procedures for receiving, reviewing, and evaluating complaints
by a formally designated unit. <a href="/s/opinion/55b1904f2846408357ee26266414a254/document/XMJ9KK003?jcsearch=21%20cfr%20820%20198&amp;summary=yes#jcite">21 C.F.R. &sect; 820.198</a>. These
procedures must ensure that all complaints are processed in a
uniform and timely manner, and that oral complaints are
documented upon receipt. <a href="/s/opinion/55b1904f2846408357ee26266414a254/document/XMJ9KK003?jcsearch=21%20C.F.R.%20%20820.198(a)&amp;summary=yes#jcite">Section 820.198(a)</a>. A manufacturer
must review and evaluate all complaints to determine whether an
investigation is necessary, and if it chooses not to
investigate, must record its reasons and the name of the
individual responsible for a decision not to investigate.
<a href="/s/opinion/55b1904f2846408357ee26266414a254/document/XMJ9KK003?jcsearch=21%20C.F.R.%20%20820.198(b)&amp;summary=yes#jcite">Section 820.198(b)</a>. When a complaint describes an event that
must be reported to the FDA, the records of the investigation
must contain enumerated categories of information and must be
maintained in a separate portion of the complaint files or
otherwise clearly identified. <a href="/s/opinion/55b1904f2846408357ee26266414a254/document/XMJ9KK003?jcsearch=21%20C.F.R.%20%20820.198(d)&amp;summary=yes#jcite">Section 820.198(d)</a>, <a href="/s/opinion/55b1904f2846408357ee26266414a254/document/XMJ9KK003?jcsearch=21%20C.F.R.%20%20820.198(e)&amp;summary=yes#jcite">(e).</a>
<span CLASS="page_no" data-cite="676 f 3d 1165" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1165" data-primary-citation="676 F.3d 1159">[*1165]</span> 
If the FDA determines that a notification to physicians is
necessary to eliminate an unreasonable risk of substantial harm
to the public health, the FDA can order the manufacturer to
issue the notification after consulting with the manufacturer.
<a href="/s/opinion/55b1904f2846408357ee26266414a254/document/XEI5PS003?jcsearch=21%20U.S.C.%20%20360h(a)&amp;summary=yes#jcite">21 U.S.C. &sect; 360h</a>(a).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  In contrast, Arizona common law imposes liability on a
manufacturer that fails to exercise reasonable care to inform a
consumer of its product's dangerous condition or of the facts
that make the product likely to be dangerous, if the
manufacturer knows or has reason to know that the product is
likely <span CLASS="page_no" data-cite="2012 bl 92098 p 6" data-cite-type="Bloomberg" data-cite-pageno="6" data-primary-citation="">[**6]</span> to be dangerous and has no reason to believe that the
consumer will realize its dangerous condition. <i>Anguiano v.</i>
<i>E.I. Du Pont De Nemours &amp; Co., Inc.</i>, <a href="/s/opinion/55b1904f2846408357ee26266414a254/document/X3M43J?jcsearch=44%20f%203d%20806&amp;summary=yes#jcite">44 F.3d 806</a>,
<a href="/s/opinion/55b1904f2846408357ee26266414a254/document/X3M43J?jcsearch=44%20f%203d%20806&amp;summary=yes#jcite">811-12</a> (9th Cir. 1995). The federal regulations that Medtronic
is alleged to have violated, which require investigation and
disclosure to the FDA in a particular manner so that the FDA
can make a decision whether notification of consumers is
necessary, are not tied to this general duty to warn consumers
under Arizona law. Thus, the Stengels' failure-to-warn claims,
to the extent they survive express preemption, exist solely by
virtue of the FDCA disclosure requirements and are, therefore,
impliedly preempted.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Nothing in our holding requires preemption of all state claims
challenging the safety of a medical device that has received
premarket approval. But as another court aptly put it, it is "a
narrow gap through which a plaintiffs state-law claim must fit
if it is to escape express or implied preemption." <i>In re</i>
<i>Medtronic, Inc., Sprint Fidelis Leads Prods. Liab. Litig.</i>,
<a href="/s/opinion/55b1904f2846408357ee26266414a254/document/X1EBQAK003?jcsearch=623%20f%203d%201200&amp;summary=yes#jcite">623 F.3d 1200</a>, <a href="/s/opinion/55b1904f2846408357ee26266414a254/document/X1EBQAK003?jcsearch=623%20f%203d%201200&amp;summary=yes#jcite">1204</a> (8th Cir. 2010), <i>quoting Riley v. Cordis</i>
<i>Corp.</i>, <a href="/s/opinion/55b1904f2846408357ee26266414a254/document/X1B6776003?jcsearch=625%20f%20supp%202d%20769&amp;summary=yes#jcite">625 F.Supp.2d 769</a>, <a href="/s/opinion/55b1904f2846408357ee26266414a254/document/X1B6776003?jcsearch=625%20f%20supp%202d%20769&amp;summary=yes#jcite">777</a> (D.Minn. 2009). At least some
claims have proven capable of passing through that gap. For
instance, in <i>Bausch v. Stryker Corp.</i>, the Seventh
Circuit held that state claims based on manufacturing defects
were not preempted under <i>Buckman</i> because, "[w]hile
there may not be a `traditional slate tort law' claim for an
`adulterated' product in so many words, the federal definition
of adulterated medical devices is tied directly to the duty of
manufacturers to avoid foreseeable dangers with their products
by complying with federal law." <a href="/s/opinion/55b1904f2846408357ee26266414a254/document/X1EOF96003?jcsearch=630%20f%203d%20546&amp;summary=yes#jcite">630 F.3d 546</a>, <a href="/s/opinion/55b1904f2846408357ee26266414a254/document/X1EOF96003?jcsearch=630%20f%203d%20546&amp;summary=yes#jcite">557</a> (7th
Cir. 2010). We offer no opinion as to whether a particular state
claim that is tied directly to compliance with federal law
would be preempted under <i>Buckman.</i> In this case, the
duty of manufacturers under federal law to report to the FDA
information regarding their devices is not tied directly to the
duty of manufacturers under state law to warn consumers of a
device's dangerous condition. On the contrary, the enforcement
of the duty to report is an element of the federal scheme that
is committed solely to the federal government.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The Stengels contend that <i>Buckman</i> is distinguishable
because it only requires preemption of fraud-on-the-FDA-type
claims where the FDA has not previously determined that the
manufacturer violated federal reporting requirements. A warning
letter from the FDA to Medtronic was attached to the proposed
amended complaint, and shows that the FDA had already
determined that Medtronic violated its federal disclosure
obligations. Thus, the Stengels contend, they could prove their
claims without second-guessing the FDA's decision making.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  We are not convinced by the Stengels' attempt to distinguish
<i>Buckman</i> because it is based on the concurrence in
<i>Buckman</i>, which disagreed with the majority
specifically because the majority did not take the position now
advocated by the Stengels. <i>See</i> <a href="/s/opinion/55b1904f2846408357ee26266414a254/document/X4U3HP?jcsearch=531%20us%20341&amp;summary=yes#jcite">531 U.S. at 354</a>,
<a href="/s/opinion/55b1904f2846408357ee26266414a254/document/1?citation=121%20supreme%20court%201012&amp;summary=yes#jcite">121 S.Ct. 1012</a> (Stevens, J., concurring in the judgment). The
<i>Buckman</i> majority's rationale, unlike the
<span CLASS="page_no" data-cite="676 f 3d 1166" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1166" data-primary-citation="676 F.3d 1159">[*1166]</span> 
concurrence's, was not solely based on a desire to avoid
jurors second-<span CLASS="page_no" data-cite="2012 bl 92098 p 7" data-cite-type="Bloomberg" data-cite-pageno="7" data-primary-citation="">[**7]</span> guessing the FDA's decision making; it was also
based on the idea that state fraud-on-the-FDA claims would
"exert an extraneous pull on the scheme established by
Congress," in which the FDA was supposed to enforce the FDCA's
disclosure requirements. <i></i><a href="/s/opinion/55b1904f2846408357ee26266414a254/document/X4U3HP?jcsearch=531%20U.S.%20at%20354&amp;summary=yes#jcite">Id. at 353</a>, <a href="/s/opinion/55b1904f2846408357ee26266414a254/document/1?citation=121%20supreme%20court%201012&amp;summary=yes#jcite">121 S.Ct. 1012</a>
(majority opinion). The majority's rationale remains relevant
in this case, even where the FDA has issued a warning letter
describing Medtronic's regulatory violations.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  We acknowledge that there is a division among the circuits
whether state failure-to-warn claims are preempted by
<i>Buckman.</i> On one hand, the Eighth Circuit has held that
federal law impliedly preempts a state failure-to-warn claim to
the extent the claim is based on the defendant's failure to
provide the FDA with sufficient information and failure to file
adverse event reports timely. <i>See In re Medtronic</i>,
<a href="/s/opinion/55b1904f2846408357ee26266414a254/document/X1EBQAK003?jcsearch=623%20f%203d%201200&amp;summary=yes#jcite">623 F.3d at 1205-06</a>. On the other hand, the Fifth Circuit has held
that a state failure-to-warn claim is not preempted. <i>See</i>
<i>Hughes v. Boston Scientific Corp.</i>, <a href="/s/opinion/55b1904f2846408357ee26266414a254/document/X1ESLIK003?jcsearch=631%20f%203d%20762&amp;summary=yes#jcite">631 F.3d 762</a>, <a href="/s/opinion/55b1904f2846408357ee26266414a254/document/X1ESLIK003?jcsearch=631%20f%203d%20762&amp;summary=yes#jcite">775-76</a>
(5th Cir. 2011).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <i>Hughes</i> is not persuasive. First, it erroneously
distinguished <i>Buckman</i> on the ground that the
plaintiffs in <i>Buckman</i> "were attempting to assert a
freestanding federal cause of action," <i>Hughes</i>,
<a href="/s/opinion/55b1904f2846408357ee26266414a254/document/X1ESLIK003?jcsearch=631%20f%203d%20762&amp;summary=yes#jcite">631 F.3d at 775</a>, notwithstanding that <i>Buckman</i> described
the claims at issue as seeking damages "under state tort law,"
<i>Buckman</i>, <a href="/s/opinion/55b1904f2846408357ee26266414a254/document/X4U3HP?jcsearch=531%20us%20341&amp;summary=yes#jcite">531 U.S. at 343</a>, <a href="/s/opinion/55b1904f2846408357ee26266414a254/document/1?citation=121%20supreme%20court%201012&amp;summary=yes#jcite">121 S.Ct. 1012</a>.
<i>Buckman's</i> preemptive reach clearly extends to state
law causes of action. <i>See Nathan Kimmel, Inc. v.</i>
<i>DowElanco</i>, <a href="/s/opinion/55b1904f2846408357ee26266414a254/document/X51GCE?jcsearch=275%20f%203d%201199&amp;summary=yes#jcite">275 F.3d 1199</a>, <a href="/s/opinion/55b1904f2846408357ee26266414a254/document/X51GCE?jcsearch=275%20f%203d%201199&amp;summary=yes#jcite">1206</a> (9th Cir. 2002)
(interference with prospective economic advantage claim
preempted); <i>see also PhotoMedex, Inc. v. Irwin</i>,
<a href="/s/opinion/55b1904f2846408357ee26266414a254/document/X1D1TA0003?jcsearch=601%20f%203d%20919&amp;summary=yes#jcite">601 F.3d 919</a>, <a href="/s/opinion/55b1904f2846408357ee26266414a254/document/X1D1TA0003?jcsearch=601%20f%203d%20919&amp;summary=yes#jcite">924</a> (9th Cir. 2010) ("The Supreme Court made clear in
<i>Buckman</i> that [<a href="/s/opinion/55b1904f2846408357ee26266414a254/document/XEI5N0003?jcsearch=21%20U.S.C.%20%20337(a)&amp;summary=yes#jcite">21 U.S.C. &sect; 337</a>(a)] also limits the
ability of a private plaintiff to pursue claims under state law
theories where such claims collide with the exclusive
enforcement power of the federal government").
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Second, <i>Hughes</i> distinguished <i>Buckman</i> because
the claims "[did] not depend on speculation that the FDA would
have taken any particular regulatory action in response to
violation of the regulations at issue, as in <i>Buckman."</i>
<i>Hughes</i>, <a href="/s/opinion/55b1904f2846408357ee26266414a254/document/X1ESLIK003?jcsearch=631%20f%203d%20762&amp;summary=yes#jcite">631 F.3d at 775</a>. But this reasoning follows the
rationale adopted by Justice Stevens in his concurrence.
<i>See</i> <a href="/s/opinion/55b1904f2846408357ee26266414a254/document/X4U3HP?jcsearch=531%20us%20341&amp;summary=yes#jcite">531 U.S. at 354</a>, <a href="/s/opinion/55b1904f2846408357ee26266414a254/document/1?citation=121%20supreme%20court%201012&amp;summary=yes#jcite">121 S.Ct. 1012</a> (Stevens, J.,
concurring in the judgment). The <i>Buckman</i> majority
never adopted this limitation on its holding.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Third, <i>Hughes</i> argued that allowing preemption would be
inconsistent with <i>Riegel's</i> recognition that "parallel"
claims are not preempted. <a href="/s/opinion/55b1904f2846408357ee26266414a254/document/X1ESLIK003?jcsearch=631%20f%203d%20762&amp;summary=yes#jcite">631 F.3d at 775</a>. But <i>Riegel</i>
established only that such claims would not be
<i>expressly</i> preempted by <a href="/s/opinion/55b1904f2846408357ee26266414a254/document/XEI5Q2003?jcsearch=21%20U.S.C.%20%20360k&amp;summary=yes#jcite">section 360k</a>. <a href="/s/opinion/55b1904f2846408357ee26266414a254/document/X18HPKU003?jcsearch=552%20us%20312&amp;summary=yes#jcite">552 U.S. at 330</a>,
<a href="/s/opinion/55b1904f2846408357ee26266414a254/document/1?citation=128%20supreme%20court%20999&amp;summary=yes#jcite">128 S.Ct. 999</a>. Since the claims before the Court in
<i>Riegel</i> failed under express preemption, the Court had
no reason to discuss implied preemption at all. <i>See</i>
<i><a href="/s/opinion/55b1904f2846408357ee26266414a254/document/X18HPKU003?jcsearch=552%20U.S.%20at%20330&amp;summary=yes#jcite">id</a>.</i> We join the Eighth Circuit in holding that a
failure-to-warn claim based on failure to provide disclosures
to the FDA is impliedly preempted.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
                                   <b>IV.</b>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Finally, we turn to the additional grounds for reversal offered
by the Stengels. They argue that the district court should have
allowed them to amend their complaint after removal to conform
to the federal pleading standard set forth in <i>Bell Atlantic</i>
<i>Corp. v. Twombly</i>, <a href="/s/opinion/55b1904f2846408357ee26266414a254/document/X17292G003?jcsearch=550%20us%20544&amp;summary=yes#jcite">550 U.S. 544</a>, <a href="/s/opinion/55b1904f2846408357ee26266414a254/document/1?citation=127%20supreme%20court%201955&amp;summary=yes#jcite">127 S.Ct. 1955</a>,
<a href="/s/opinion/55b1904f2846408357ee26266414a254/document/X17292G003?jcsearch=167%20l%20ed%202d%20929&amp;summary=yes#jcite">167 L.Ed.2d 929</a> (2007). However, the district court did not dismiss
the Stengels' complaint on the ground that <span CLASS="page_no" data-cite="2012 bl 92098 p 8" data-cite-type="Bloomberg" data-cite-pageno="8" data-primary-citation="">[**8]</span> it did not conform
to the <i>Twombly</i> standard,
<span CLASS="page_no" data-cite="676 f 3d 1167" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1167" data-primary-citation="676 F.3d 1159">[*1167]</span> 
but instead on the ground that the Stengels' claims were
preempted.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Next, the Stengels contend that the district court erred by
failing to convert Medtronic's motion to dismiss into a motion
for summary judgment and then refusing to grant a continuance
for discovery under Federal Rule of Civil Procedure <a href="/s/opinion/55b1904f2846408357ee26266414a254/document/1?citation=FRCIVPRO%2056&amp;summary=yes#jcite">56</a>(f).<a HREF="#fn200" name="fnref_fn200">[fn2]</a>
This contention fails as well. The district court took judicial
notice of the fact that Medtronic's pain pump received
premarket approval as demonstrated by FDA records. A court may
consider facts extraneous to a complaint on a motion to
dismiss, without converting the motion into one for summary
judgment, if such facts are judicially noticeable under Federal
Rule of Evidence <a href="/s/opinion/55b1904f2846408357ee26266414a254/document/X135KKA003?jcsearch=Fed.%20R.%20Evid.%20201&amp;summary=yes#jcite">201</a>. <i>Lee v. City of Los Angeles</i>,
<a href="/s/opinion/55b1904f2846408357ee26266414a254/document/X50REO?jcsearch=250%20f%203d%20668&amp;summary=yes#jcite">250 F.3d 668</a>, <a href="/s/opinion/55b1904f2846408357ee26266414a254/document/X50REO?jcsearch=250%20f%203d%20668&amp;summary=yes#jcite">688-89</a> (9th Cir. 2001). A court may take judicial
notice of a fact that "is not subject to reasonable dispute
because it . . . can be accurately and readily determined from
sources whose accuracy cannot reasonably be questioned."
Fed.R.Evid. <a href="/s/opinion/55b1904f2846408357ee26266414a254/document/X135KKA003?jcsearch=Fed.%20R.%20Evid.%20201(b)&amp;summary=yes#jcite">201</a>(b). Because the accuracy of FDA records cannot
reasonably be questioned, the premarket approval status of
Medtronic's pump is a fact subject to judicial notice. <i>See</i>
<i>Funk v. Stryker Corp.</i>, <a href="/s/opinion/55b1904f2846408357ee26266414a254/document/X1ETR4E003?jcsearch=631%20f%203d%20777&amp;summary=yes#jcite">631 F.3d 777</a>, <a href="/s/opinion/55b1904f2846408357ee26266414a254/document/X1ETR4E003?jcsearch=631%20f%203d%20777&amp;summary=yes#jcite">783</a> (5th Cir. 2011)
(affirming judicial notice of FDA letter granting premarket
approval). The district court thus did not abuse its discretion
in considering this fact in connection with the motions to
dismiss.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Finally, the Stengels contend that the district court erred by
not ruling on their request to take judicial notice of
Medtronic's correction letter and a document showing that the
pump was ultimately recalled in 2008. But the district court
did not need to take judicial notice of the correction letter
because that document was included as an exhibit to the
proposed amended complaint and, therefore, was part of the
pleadings. Moreover, regardless of whether judicial notice
would have been proper, it was not necessary because the facts
that Medtronic sent a correction letter and that the FDA issued
a recall on the pump do not affect the preemption analysis. Any
error in the district court's failure to rule on the request
for judicial notice was harmless and, therefore, is not
reversible. <i>See Sanchez v. Aerovias De Mexico, S.A. De</i>
<i>C.V.</i>, <a href="/s/opinion/55b1904f2846408357ee26266414a254/document/X1CBSM8003?jcsearch=590%20f%203d%201027&amp;summary=yes#jcite">590 F.3d 1027</a>, <a href="/s/opinion/55b1904f2846408357ee26266414a254/document/X1CBSM8003?jcsearch=590%20f%203d%201027&amp;summary=yes#jcite">1029</a> (9th Cir. 2010).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
                                   <b>V.</b>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  We recognize that it may seem harsh to deny compensation to a
person who alleges serious injury from a medical device. But
such is the direction from the Supreme Court for cases like the
one before us. We are required to follow the Court.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  To the extent the Stengels' claims are based on the theory that
state law required Medtronic to warn consumers about the
dangerous condition of its pain pumps without first receiving
an order to do so from the FDA, the state law establishes a
requirement different from the requirements of the FDCA. See
<a href="/s/opinion/55b1904f2846408357ee26266414a254/document/XEI5Q2003?jcsearch=21%20usc%20360k&amp;summary=yes#jcite">21 U.S.C. &sect; 360k</a>; <i>Riegel</i>, <a href="/s/opinion/55b1904f2846408357ee26266414a254/document/X18HPKU003?jcsearch=552%20us%20312&amp;summary=yes#jcite">552 U.S. at 325</a>,
<a href="/s/opinion/55b1904f2846408357ee26266414a254/document/1?citation=128%20supreme%20court%20999&amp;summary=yes#jcite">128 S.Ct. 999</a>. To the extent the Stengels' claims are based on a theory
that Medtronic caused them injury by failing to comply with its
duty to report information to the FDA, then-claims threaten to
skew the delicate balance of statutory objectives sought to be
achieved by the FDCA. <i>See Buckman</i>, <a href="/s/opinion/55b1904f2846408357ee26266414a254/document/X4U3HP?jcsearch=531%20us%20341&amp;summary=yes#jcite">531 U.S. at 348</a>,
<a href="/s/opinion/55b1904f2846408357ee26266414a254/document/1?citation=121%20supreme%20court%201012&amp;summary=yes#jcite">121 S.Ct. 1012</a>. Congress <span CLASS="page_no" data-cite="2012 bl 92098 p 9" data-cite-type="Bloomberg" data-cite-pageno="9" data-primary-citation="">[**9]</span> has established the premarket approval
process as an important balance between getting help to
patients who need it as soon as possible and protecting
patients who will use the newly proposed help. Those who
<span CLASS="page_no" data-cite="676 f 3d 1168" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1168" data-primary-citation="676 F.3d 1159">[*1168]</span> 
have benefitted from this congressional balancing are not
before us, but they reap the benefit of Congress's insights. It
is a balance we must observe. Any change must be made by
Congress itself.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Therefore, we hold that even if some of the Stengels' claims
can be interpreted to escape express preemption, they cannot be
interpreted to escape implied preemption. The district court
correctly held that the Stengels' proposed amendment was
futile, and therefore did not abuse its discretion in denying
leave to amend. <i>See Alvarez</i>, <a href="/s/opinion/55b1904f2846408357ee26266414a254/document/X1G7T4E003?jcsearch=656%20f%203d%20925&amp;summary=yes#jcite">656 F.3d at 935</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <b>AFFIRMED.</b>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn100" name="fn100">[fn1]</a></span> The dissent argues that because the Stengels' claims are
not expressly preempted under <i>Lohr</i>, they cannot be
impliedly preempted under <i>Buckman.</i> This is not the
law. <i>Lohr</i> does not determine the scope of implied
preemption because it never considered the issue.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn200" name="fn200">[fn2]</a></span> In the 2010 amendments to the Federal Rules of Civil
Procedure, the provisions of <a href="/s/opinion/55b1904f2846408357ee26266414a254/document/X144L4C003?jcsearch=Fed.%20R.%20Civ.%20Pro.%2056(f)&amp;summary=yes#jcite">Rule 56(f)</a> were moved to
<a href="/s/opinion/55b1904f2846408357ee26266414a254/document/X144L4C003?jcsearch=Fed.%20R.%20Civ.%20Pro.%2056(d)&amp;summary=yes#jcite">Rule 56(d)</a> without substantial change.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  NOONAN, Circuit Judge, dissenting:
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The issue that this court must address is serious and the
magnitude of its potential implications is great:
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  From 2000 through 2011, more than 150 new high-risk
  medical devices were approved by the Food and Drug
  Administration (FDA) through the premarket approval
  (known as PMA) process, and an additional 600 devices
  were cleared through the less demanding 510(k)
  process, in four medical specialty areas
  (cardiovascular care, neurology, obstetrics and
  gynecology, and orthopedics; see graph Numbers of
  High-Risk (Class III) Medical Devices Approved or
  Cleared by the FDA in Cardiovascular Care, Neurology,
  Obstetrics and Gynecology, and Orthopedics,
  2000-2011.).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
"Postmarketing Surveillance of Medical Devices-Filling in the
Gaps," Frederic S. Resnic, M.D., and Sharon-Lise T. Normand,
Ph.D., February 14, 2012 (10.1056/NEJMp1114865).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Has Congress or the Supreme Court created such freedom from
liability for the manufacturers of such sensitive devices that
only in nonexistent cases are the manufacturers subject to suit
for damages? Are individuals injured by the malfunction of such
devices without remedy against the manufacturers of them? That
appears to be the conclusion of this court today with its
holding that the MDA explicitly preempts and implicitly
preempts any state remedy of damages for violation of a state
requirement paralleling the MDA.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  This conclusion, astonishing in its comprehensiveness, is
equally astonishing in the light of binding federal law as
determined by the United States Supreme Court.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <i>The law.</i> In a case involving the defendant in our
case, the Court held:
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Nothing in <a href="/s/opinion/55b1904f2846408357ee26266414a254/document/XEI5Q2003?jcsearch=21%20U.S.C.%20%20360k&amp;summary=yes#jcite">&sect; 360k</a> denies Florida the right to
  provide a traditional damages remedy for violations of
  common-law duties when those duties parallel federal
  requirements. Even if it may be necessary as a matter
  of Florida law to prove that those violations were the
  result of negligent conduct, or that they created an
  unreasonable hazard for users of the product, such
  additional elements of the state-law cause of action
  would make the state requirements narrower, not
  broader, than the federal requirement. While such a
  narrower requirement might be "different from" the
  federal rules in a literal sense, such a difference
  would surely provide a strange reason for finding
  preemption of a state rule insofar as it duplicates
  <span CLASS="page_no" data-cite="2012 bl 92098 p 10" data-cite-type="Bloomberg" data-cite-pageno="10" data-primary-citation="">[**10]</span> the federal rule. The presence of a damages remedy
  does not amount to the additional or different
  "requirement" that is necessary under the statute;
  rather, it merely provides another reason for
  manufacturers to comply with identical existing
  "requirements" under federal law.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<i>Medtronic, Inc. v. Lohr</i>, <a href="/s/opinion/55b1904f2846408357ee26266414a254/document/X5CCS2?jcsearch=518%20us%20470&amp;summary=yes#jcite">518 U.S. 470</a>, <a href="/s/opinion/55b1904f2846408357ee26266414a254/document/X5CCS2?jcsearch=518%20us%20470&amp;summary=yes#jcite">495</a>,
<a href="/s/opinion/55b1904f2846408357ee26266414a254/document/1?citation=116%20supreme%20court%202240&amp;summary=yes#jcite">116 S.Ct. 2240</a>, <a href="/s/opinion/55b1904f2846408357ee26266414a254/document/X5CCS2?jcsearch=135%20l%20ed%202d%20700&amp;summary=yes#jcite">135 L.Ed.2d 700</a> (1996).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  As the Supreme Court puts it, "common law duties" not preempted
by the express terms of the MDA may "parallel" the
<span CLASS="page_no" data-cite="676 f 3d 1169" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1169" data-primary-citation="676 F.3d 1159">[*1169]</span> 
MDA. Such "common law duties" cannot amount to zero because
the states may provide a remedy for their breach. See
<i><a href="/s/opinion/55b1904f2846408357ee26266414a254/document/X5CCS2?jcsearch=518%20U.S.%20470&amp;summary=yes#jcite">id</a>.</i> Literally, as the Supreme Court also points out,
the state may add an element to the state cause of action
without destroying the parallel with the federal requirement.
<i><a href="/s/opinion/55b1904f2846408357ee26266414a254/document/X5CCS2?jcsearch=518%20U.S.%20470&amp;summary=yes#jcite">Id</a>.</i>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  This magisterial exposition of the statute by the Supreme Court
sets out what the Supreme Court has consistently held and what
is necessary for the correct decision of our case.
<i>Nothing</i> in the statute prevents provision by a state
of "a traditional damages remedy" for violation of "state
duties" that parallel the federal requirements.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The exception to preemption stated by the Court in
<i>Lohr</i> was restated by the Court in yet another case
involving the present defendant: "<a href="/s/opinion/55b1904f2846408357ee26266414a254/document/XEI5Q2003?jcsearch=21%20U.%20S.%20C.%20%20360k&amp;summary=yes#jcite">&sect; 360k</a> does not prevent a
State from providing a damages remedy for claims premised on a
violation of FDA regulations; the state duties in such a case
`parallel,' rather than add to, federal requirements."
<i>Riegel v. Medtronic</i>, <a href="/s/opinion/55b1904f2846408357ee26266414a254/document/X18HPKU003?jcsearch=552%20us%20312&amp;summary=yes#jcite">552 U.S. 312</a>, <a href="/s/opinion/55b1904f2846408357ee26266414a254/document/X18HPKU003?jcsearch=552%20us%20312&amp;summary=yes#jcite">330</a>, <a href="/s/opinion/55b1904f2846408357ee26266414a254/document/1?citation=128%20supreme%20court%20999&amp;summary=yes#jcite">128 S.Ct. 999</a>,
<a href="/s/opinion/55b1904f2846408357ee26266414a254/document/X18HPKU003?jcsearch=169%20l%20ed%202d%20892&amp;summary=yes#jcite">169 L.Ed.2d 892</a> (2008) (quoting <i>Lohr</i>, <a href="/s/opinion/55b1904f2846408357ee26266414a254/document/X5CCS2?jcsearch=518%20us%20470&amp;summary=yes#jcite">518 U.S. at 495</a>,
<a href="/s/opinion/55b1904f2846408357ee26266414a254/document/1?citation=116%20supreme%20court%202240&amp;summary=yes#jcite">116 S.Ct. 2240</a>).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Pellucidly, the Supreme Court has twice interpreted the MDA and
held states may provide a damages remedy. In the language of
<i>Lohr</i>, it would be "strange" if the Court expressly
preserved state remedies from preemption but believed such
remedies were implicitly rejected by the statute.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Our court in our present case comes to this strange conclusion
by its reading of <i>Buckman</i>, <a href="/s/opinion/55b1904f2846408357ee26266414a254/document/X4U3HP?jcsearch=531%20us%20341&amp;summary=yes#jcite">531 U.S. at 353</a>,
<a href="/s/opinion/55b1904f2846408357ee26266414a254/document/1?citation=121%20supreme%20court%201012&amp;summary=yes#jcite">121 S.Ct. 1012</a>, where the Supreme Court disparaged the notion of an
"extraneous pull" on the MDA. This reference to "extraneous
pull" was surely a make-weight. A dictum, it does not conform
with <i>Lohr</i> or stand after <i>Riegel.</i> State;
damages do exert an additional pull for compliance with the
MDA.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <i>Buckman</i>, <a href="/s/opinion/55b1904f2846408357ee26266414a254/document/X4U3HP?jcsearch=531%20us%20341&amp;summary=yes#jcite">531 U.S. 341</a>, <a href="/s/opinion/55b1904f2846408357ee26266414a254/document/1?citation=121%20supreme%20court%201012&amp;summary=yes#jcite">121 S.Ct. 1012</a>, relied on in
our case by the majority, predated <i>Riegel</i> and
carefully distinguished <i>Lohr.</i> The plaintiffs in
<i>Buckman</i> alleged that Medtronic had committed fraud on
the FDA. <i>Buckman</i>, <a href="/s/opinion/55b1904f2846408357ee26266414a254/document/X4U3HP?jcsearch=531%20us%20341&amp;summary=yes#jcite">531 U.S. at 347</a>, <a href="/s/opinion/55b1904f2846408357ee26266414a254/document/1?citation=121%20supreme%20court%201012&amp;summary=yes#jcite">121 S.Ct. 1012</a>.
That charge did not allege a state cause of action. Fraud on a
federal agency was not a tort that the states had traditionally
penalized. <i><a href="/s/opinion/55b1904f2846408357ee26266414a254/document/X4U3HP?jcsearch=531%20U.S.%20at%20347&amp;summary=yes#jcite">Id</a>.</i> "To the contrary, the relationship
between a federal agency and the entity it regulates is
inherently federal in character. . . ." <i><a href="/s/opinion/55b1904f2846408357ee26266414a254/document/X4U3HP?jcsearch=531%20U.S.%20at%20347&amp;summary=yes#jcite">Id</a>.</i>
"Accordingly &mdash; and in contrast the situations implicating
`federalism concerns and the historic primacy of state
regulation of matters of health and safety,' . . . &mdash; no
presumption against pre-emption obtains in this case."
<i>Buckman</i>, <a href="/s/opinion/55b1904f2846408357ee26266414a254/document/X4U3HP?jcsearch=531%20us%20341&amp;summary=yes#jcite">531 U.S. at 348</a>, <a href="/s/opinion/55b1904f2846408357ee26266414a254/document/1?citation=121%20supreme%20court%201012&amp;summary=yes#jcite">121 S.Ct. 1012</a> (quoting
<i>Lohr</i>, <a href="/s/opinion/55b1904f2846408357ee26266414a254/document/X5CCS2?jcsearch=518%20us%20470&amp;summary=yes#jcite">518 U.S. at 485</a>, <a href="/s/opinion/55b1904f2846408357ee26266414a254/document/1?citation=116%20supreme%20court%202240&amp;summary=yes#jcite">116 S.Ct. 2240</a>). The Court went
on to stamp the state claims in the case as "conflict[ing]
with" the MDA and "therefore impliedly pre-empted[] by federal
law." <i><a href="/s/opinion/55b1904f2846408357ee26266414a254/document/X5CCS2?jcsearch=518%20U.S.%20at%20485&amp;summary=yes#jcite">Id</a>.</i> (footnote omitted).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The fraud-on-the-FDA claims in <i>Buckman</i> "exist[ed]
solely by virtue of the FDCA disclosure requirements" and did
not "rely[] on traditional state tort law which had <span CLASS="page_no" data-cite="2012 bl 92098 p 11" data-cite-type="Bloomberg" data-cite-pageno="11" data-primary-citation="">[**11]</span> predated
the federal enactments in question[]." <i>Id.</i> at 353,
<a href="/s/opinion/55b1904f2846408357ee26266414a254/document/1?citation=121%20supreme%20court%201012&amp;summary=yes#jcite">121 S.Ct. 1012</a>; <i>see also id.</i> at 352-53, <a href="/s/opinion/55b1904f2846408357ee26266414a254/document/1?citation=121%20supreme%20court%201012&amp;summary=yes#jcite">121 S.Ct. 1012</a>
(contrasting <i>Buckman's</i> preempted fraud-on-the-FDA
claims with the claims in <i>Lohr</i>, <a href="/s/opinion/55b1904f2846408357ee26266414a254/document/X5CCS2?jcsearch=518%20us%20470&amp;summary=yes#jcite">518 U.S. at 481</a>,
<a href="/s/opinion/55b1904f2846408357ee26266414a254/document/1?citation=116%20supreme%20court%202240&amp;summary=yes#jcite">116 S.Ct. 2240</a>, which "arose from the manufacturer's alleged
failure to use reasonable care in the production of the
product"). The claims in the present case are traditional,
free-standing tort claims, analogous to those in <i>Lohr.</i>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Not a word in <i>Buckman</i> limits <i>Lohr.</i> The
majority invoke it but do not show that it has application
here. <i>Riegel</i> demonstrates
<span CLASS="page_no" data-cite="676 f 3d 1170" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1170" data-primary-citation="676 F.3d 1159">[*1170]</span> 
that <i>Lohr</i> is still binding law determined by the
United States Supreme Court.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <i>The federal requirements.</i> The federal statutory scheme
imposes on manufacturers of medical devices a continuous
reporting obligation that applies after a device goes to
market. <a href="/s/opinion/55b1904f2846408357ee26266414a254/document/XEI5PU003?jcsearch=21%20usc%20360i&amp;summary=yes#jcite">21 U.S.C. &sect; 360i</a>. In its 2008 Warning Letter,
detailing the regulatory history, the FDA noted that
Medtronic's Educational Brief of July 2003 was "a reportable
correction under <a href="/s/opinion/55b1904f2846408357ee26266414a254/document/XMJ978003?jcsearch=21%20CFR%20806.10(A)(1)&amp;summary=yes#jcite">CFR 806.10(a)(1</a>)." Whatever information
Medtronic gave its physician customers, it had not reported its
action to the FDA as a correction. The FDA Warning Letter told
Medtronic the incidents of formation of an inflammatory mass at
the catheter tip between November 2000 and July 2006 "had not
yet been communicated to customers," that is, the physicians.
The FDA letter told Medtronic that the FDA "disagrees with your
conclusion that the July 2003 Educational Brief was not a
correction or removal." The new labeling in 2003, the FDA told
Medtronic, had not been communicated to physicians "whose
patients already had a SynchroMed pump implanted within them."
Stengel's doctor was in this category of physicians uninformed
of the new information.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  These failures of Medtronic to report are identified in the FDA
letter as acts in violation of the federal statute and the
regulations applying it. Under the FDA's assessment of its
conduct, Medtronic was in violation of federal law as early as
2003 because it failed to adequately respond to events
indicating that its device posed a specific danger.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <i>The parallel state claims.</i> The Stengels sought to
amend their original complaint to allege that Medtronic
negligently failed "to provide adequate warnings, information,
or both, of the risks and hazards of the pain pump." The
Arizona Supreme Court has recognized a cause of action based on
a manufacturer's failure to remedy or give notice of an
unreasonably dangerous condition discovered post-market.
<i>See Readenour v. Marion Power Shovel</i>, <a href="/s/opinion/55b1904f2846408357ee26266414a254/document/X9TOGA?jcsearch=149%20arizona%20442&amp;summary=yes#jcite">149 Ariz. 442</a>,
<a href="/s/opinion/55b1904f2846408357ee26266414a254/document/X9TOGA?jcsearch=149%20arizona%20442&amp;summary=yes#jcite">448</a>, <a href="/s/opinion/55b1904f2846408357ee26266414a254/document/X9TOGA?jcsearch=719%20pacific%202d%201058&amp;summary=yes#jcite">719 P.2d 1058</a> (1986) (plaintiff could argue that
manufacturer, upon discovering "an unreasonably dangerous
condition at any time during the product's history[,]" should
have either retrofitted "each of the models already sold or
warn[ed] each of the buyers of the existence of the latent
danger"). That Medtronic discovered the danger of granuloma
formation after the pain pump went to market does not defeat
the Stengels' cause of action under Arizona law. <i>See</i>
<i><a href="/s/opinion/55b1904f2846408357ee26266414a254/document/X9TOGA?jcsearch=149%20Ariz.%20442&amp;summary=yes#jcite">id</a>.</i>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Whether the state law claim has elements that further
<i>restrict</i> its application is of no import. <i>See</i>
<i>Lohr</i>, <a href="/s/opinion/55b1904f2846408357ee26266414a254/document/X5CCS2?jcsearch=518%20us%20470&amp;summary=yes#jcite">518 U.S. at 495</a>, <a href="/s/opinion/55b1904f2846408357ee26266414a254/document/1?citation=116%20supreme%20court%202240&amp;summary=yes#jcite">116 S.Ct. 2240</a>. The Stengels have
alleged a valid parallel state law cause <span CLASS="page_no" data-cite="2012 bl 92098 p 12" data-cite-type="Bloomberg" data-cite-pageno="12" data-primary-citation="">[**12]</span> of action. Arizona law
imposes requirements that parallel the requirements under
federal law, and Arizona law provides a remedy in damages for
the violation of the state requirement.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <i>The state claim for damages.</i> In their proposed
amendment, the Stengels sought the state remedy of damages for
the injuries suffered by Richard Stengel as a consequence of
Medtronic's failure to warn of the danger posed by its pump.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  To sum up, the Stengels seek to amend their, complaint to
assert Arizona requirements that parallel federal requirements
under the MDA and for which Arizona provides a remedy in
damages. The amendments should be allowed.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
                                Appendix
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The FDA Warning Letter, addressed to the CEO of Medtronic, July
3, 2008, setting out the history of reports of the inflammatory
mass, states:
<span CLASS="page_no" data-cite="676 f 3d 1171" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1171" data-primary-citation="676 F.3d 1159">[*1171]</span> 
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <b>A correction or removal conducted to reduce a</b>
  <b>risk to health posed by a device was not reported in</b>
  <b>writing to FDA, as required by</b>
  <b>21 CFR</b> 806.10(a)(1).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  In July 2003 your establishment sent a letter with an
  enclosed "EDUCATIONAL BRIEF," entitled "Information
  about Inflammatory Mass," to SynchroMed customers
  (physicians). Also enclosed were reprints of two
  articles published in the December 2002 issue of Pain
  Medicine and revised labeling for the SynchroMed
  Technical Manual. FDA defines a "correction" in
  <a href="/s/opinion/55b1904f2846408357ee26266414a254/document/XMJ974003?jcsearch=21%20CFR%20806.2(D)&amp;summary=yes#jcite">21 CFR 806.2</a>(d) as ". . . the repair, modification,
  adjustment, relabeling, destruction, or inspection
  (including patient monitoring) of a device without its
  physical removal from its point of use to some other
  location." FDA believes that the July 2003 Educational
  Brief, which was sent to all customers using
  SynchroMed pumps, meets the definition of "correction"
  in that the letter provided updated labeling to
  customers for devices that were already in
  distribution.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The FDA also believes that the July
  2003 Educational Brief is a reportable correction under
  <a href="/s/opinion/55b1904f2846408357ee26266414a254/document/XMJ978003?jcsearch=21%20CFR%20806.10(a)(1)&amp;summary=yes#jcite">21 CFR 806.10</a>(a)(1) in that the letter contained specific
  information intended to reduce the risk to health
  posed by the device. For example, the July 2003
  Educational Brief specifically states that "[i]f an
  inflammatory mass is detected in its clinical course,
  prompt discontinuation of opioid delivery into the
  mass may cause it to shrink or disappear without the
  need for surgical removal." The letter also
  specifically recommends catheter replacement,
  repositioning, and other interventional procedures,
  depending on the patient's clinical condition. These
  recommendations were neither included in the pump's
  original labeling, nor conveyed to customers in a
  January 2001 communication regarding inflammatory
  masses.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Additionally, the July 2003 Educational Brief
  contained new "Post implant" warnings that suggest
  that clinicians should routinely monitor patients for
  prodromal clinical signs or symptoms of inflammatory
  mass such as change in character, quality or intensity
  of pain; reports of new radicular pain, especially at
  or near the dermatomal level of the catheter tip;
  frequent or large escalations of daily drug does to
  maintain the analgesic effect; and dose escalations
  that may only temporarily alleviate <span CLASS="page_no" data-cite="2012 bl 92098 p 13" data-cite-type="Bloomberg" data-cite-pageno="13" data-primary-citation="">[**13]</span> the patient's
  increasing pain. These new warnings were not included
  in the January 2001 letter or the pump's original
  technical manual.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Furthermore, the journal articles included with the
  July 2003 Educational Brief stated with regard to
  adverse event reporting that 41 adverse events
  regarding inflammatory mass were identified as of
  November 2000 (conveyed to customers in the January
  2001 letter). The articles also state that an
  additional 51 events were identified after the 2001
  letter had been distributed to customers. The
  articles suggest that the number of new adverse events has more
  than doubled in one year of reporting. It is
  noteworthy that during the most recent inspection of
  your facility, your firm calculated the current rate
  of inflammatory masses to be approximately
  [<b>redacted</b>] events per [<b>redacted</b>]
  implants. This figure, which has not yet been
  communicated to your customers, suggests that the risk
  of inflammatory masses occurring at or near the tip of
  intrathecal catheters used with SynchroMed pumps is
  [<b>redacted</b>] greater
<span CLASS="page_no" data-cite="676 f 3d 1172" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1172" data-primary-citation="676 F.3d 1159">[*1172]</span> 
  than the [<b>redacted</b>] rate indicated in the
  January 2001 letter.
</p></div>
<!--BBLS DD 1699955605507-->

</div>
<div class='sideBar printHide clearfix '>
<!-- /Default state -->
<!-- /Display properties -->
<div class='tabsNotepad printHide'>
<div class='tabButtons clearfix'>
<div class='borderTab activeTab' id='buttonTab_general'>
<span>
General Info
</span>
</div>
<div class='borderTab inactiveTab' id='buttonTab_notePad'>
<span>Notepad</span>
</div>
</div>
</div>
<div class='sideBarInner clearfix'>
<div class='sideBarContent bootstrap sidebar ' id='tab_general'>
<div class='sidebarSection'>
<div class='sidebarTitle'>
<span class='left'>BCite Analysis</span>
</div>
<div class='sidebarSubsection sidebarSectionDivider bciteRenderer clearfix'>
<div class='sidebarSubhead bold'>
<a href="/bcite/X1HF6K0003/history">Direct History (3)</a>
</div>
<div class='sidebarItemLabel bold'>
No Negative Direct History
</div>
</div>
<div class='bciteRenderer clearfix sidebarSectionDivider sidebarSubsection'>
<div class='sidebarSubhead bold'>
<a href="/bcite/X1HF6K0003/analysis">Case Analysis (5)</a>
</div>
<div class='bciteResult'>
<img class='icon printOnly' src='/images/citation_icons/positive.png'>
<div class='citation icon positive printHide' title='Positive'></div>
<a class='citationAnalysisLabel' href='/bcite/X1HF6K0003/analysis?analysis=BCITE_POSITIVE_GROUP'>
Positive
</a>
<span class='citationNumberLabel'>
5
</span>
</div>
</div>
<div class='sidebarSubsection clearfix analysisLink'>
<div class='sidebarSubhead small'>
<a href="https://www.bloomberglaw.com/help/BCite_Indicators.htm" class="citatorRenderer">Description of BCite Indicators</a>
</div>
</div>

<div id='generalInfo'>
<div class='sidebarSection'>
<div class='sidebarTitle'>
<span>
General Information
</span>
</div>
<div class='sidebarSubsection sidebarSectionDivider'><div class='facetItemHeading'>Result(s)</div><div class='facetItemLabel'>Judgment Affirmed</div></div>
<div class='sidebarSubsection sidebarSectionDivider'><div class='facetItemHeading'>Related Docket(s)</div><div class='facetItemLabel'><a href="/s/opinion/55b1904f2846408357ee26266414a254/document/X1Q6LG1A7NO2">10-17755 (9th Cir.)</a></div></div><div class='sidebarSubsection sidebarSectionDivider'><div class='facetItemHeading'>Topic(s)</div><div class='facetItemLabel'>Civil Procedure</div><div class='facetItemLabel'>Evidence</div><div class='facetItemLabel'>Products Liability</div></div>
<div class='sidebarSubsection' id='judges_section'>
<div class='facetItemHeading'>Judge(s)</div>
<div id='judges_section_loader'></div>
</div>
</div>
</div>
</div>
</div>
<div class='sideBarContent clearfix notepad hidden' id='tab_notePad'>
<div id='notepad'>
<div class='notepadInstructions'>
Click anywhere in Notepad to add a note.
</div>
<div class='protoNote note'>
<a class='anchor'></a>
<div class='headerRow'>
<div class='ieFloat'>
<span class='title'></span>
<span class='date'></span>
</div>
<div class='ieFloat right'>
<a class='delete'>
Delete
</a>
<div class='toolDivider'>
|
</div>
<a class='edit'>
Edit
</a>
</div>
<div class='clearfix'></div>
</div>
<div class='body'></div>
<div class='footer'>
<div class='ieFloat'>
<a class='previous'>
Previous
</a>
</div>
<div class='ieFloat pageDisplay'>
<span class='numNoteDisplay'></span>
</div>
<div class='ieFloat right'>
<a class='next'>
Next
</a>
</div>
</div>
</div>
<div class='protoNoteEditor note'>
<div class='headerRow'>
<div class='ieFloat'>
<span class='title'></span>
<span class='date'></span>
</div>
</div>
<div class='body'>
<textarea class='contents'></textarea>
<div class='toolRow'>
<a class='save'>
Save
</a>
<div class='toolDivider'>
|
</div>
<a class='cancel'>
Cancel
</a>
<div class='clearfix'></div>
</div>
</div>
<div class='footer'>
<div class='ieFloat'>
<a class='previous disabled'>
Previous
</a>
</div>
<div class='ieFloat pageDisplay'>
<span class='numNoteDisplay disabled'></span>
</div>
<div class='ieFloat right'>
<a class='next disabled'>
Next
</a>
</div>
</div>
</div>
<div class='protoConfirmDelete'>
<div class='popupWindowOuter'>
<div class='popupWindowInner'>
<div class='clearfix popupTitle'>
<div class='close' onclick='closePopup()'></div>
<h2>
Delete Note
</h2>
</div>
<div class='popupContent'>
<div class='sectionLabel'>
Are you sure you want to delete this note?
<br>
<br>
<br>
<br>
</div>
</div>
<div class='popUpActions'>
<button class='bootstrap skinButton popup action right'>
<span>
Delete
</span>
</button>
<button class='bootstrap skinButton popup cancel right' onclick='closePopup()'>
<span>
Cancel
</span>
</button>
</div>
</div>
</div>
</div>
</div>

</div>
</div>

</div>
<div class='clearfix'></div>
</div>

<div class='keywordSearch' id='keyword_search'>
<a href="javascript:Blaw__findPrevKeyWord();redrawPrevNextButtons();" id="keyword_search_previous">Previous Keyword</a>
|
<a href="javascript:Blaw__findNextKeyWord();redrawPrevNextButtons();" id="keyword_search_next">Next Keyword</a>
</div>
<div class='pageLoader'></div>
<div class='browserPopupContainer' id='browserPopup'>
<div class='browserTitle'>
<div class='close' onclick='$("#browserPopup").bbTocBrowser(false);'></div>
<h2 class='popup_title'></h2>
</div>
<div class='browserPopupContent popup_content' id='browserPopupContent'></div>
</div>
<div class='maskOverlay' id='ajax_browser_mask'></div>


<div class='clearfix'></div>
</div>
</div>
<!-- _enter_client_matter.haml begin -->
<div class='clientMatterContainer hidden' id='clientMatterContainer'>
<form accept-charset="UTF-8" action="/client_matter/session/create" id="startClientMatterSessionForm" method="post"><div style="margin:0;padding:0;display:inline"><input name="utf8" type="hidden" value="&#x2713;" /><input name="authenticity_token" type="hidden" value="NiJ+70/qv61N1TFnbttr4ZzRa7IGhB5DMvou0CKGUXA=" /></div>
<input id="create_client_matter" name="create_client_matter" type="hidden" value="false" />
<div class='clearfix popupTitle'>
<div class='close' onclick='cancelClientMatterPopup()'></div>
<h2>
Enter a Client Matter
</h2>
</div>
<div class='popUpContent'>
<div class='clientMatterPopupHeader'>
Your firm optionally allows a client matter to be selected while you are using Bloomberg Law.
Please select from a recently used Client Matter or enter a Client Matter manually.
</div>
<div class='error' id='clientMatterLabelErrors' style='display:none'></div>
<div class='error' id='attorneyNumberLabelErrors' style='display:none'></div>
<div class='row sources clearfix'>
<div class='labelHolder'>
<span class='label'>Client Matter</span>
</div>
<div class='inputContainer'>
<input autocomplete="off" class="autocompleteTextField input_auto autocompleteForm" data-context="CLIENT_MATTERS" data-highlight-term="true" data-select-callback="applyClientMatterFromAutocompleteSelection" data-show-no-matches="false" data-url="/autocomplete/lookup" id="client_matter_label" name="client_matter_label" type="text" value="" />
<script type="text/javascript">
//<![CDATA[
jQuery().ready(function ($) { $('#client_matter_label').bbAutocomplete(); });
//]]>
</script>
</div>
</div>
<div class='row clientMatterSuppressionCheckholder' id='clientMatterSuppressionCheckholder'>
<label>
<input id="suppress_client_matter_prompt_enabled" name="suppress_client_matter_prompt_enabled" type="hidden" value="1" />
<input checked="checked" id="suppress_client_matter_prompt" name="suppress_client_matter_prompt" type="checkbox" value="1" />
<label for="suppress_client_matter_prompt">Do not remind me again this session</label>
</label>
</div>
<div class='clientMatterText'>
Please contact your administrator if you have questions about client matter.
</div>
</div>
<div class='popUpActions'>
<button class='bootstrap skinButton popup right' type='submit'>
<span>
Submit
</span>
</button>
<button class='bootstrap skinButton popup cancel right' onclick='cancelClientMatterPopup();' type='button'>
<span>
Cancel
</span>
</button>
</div>
</form>

<div id='createClientMatterForm' style='display:none'>
<div class='clearfix popupTitle'>
<h2>
Unrecognized Client Matter
</h2>
</div>
<div class='div'>
Client Matter
<span id='new_client_matter_label'>&nbsp;</span>
does not currently exist in Bloomberg Law. Would you like to add this client matter to the system?
</div>
<div class='popUpActions'>
<button class='bootstrap skinButton popup action right' type='button'>
<span>
Yes
</span>
</button>
<button class='bootstrap skinButton popup cancel right' type='button'>
<span>
No
</span>
</button>
</div>
</div>
</div>
<!-- _enter_client_matter.haml begin -->

<div id='loading_container'></div>
<div class='fixedControls menuHolder printHide' id='bottom_menu_row'>
<div class='menuButton' id='pde_tray_menu'>
<div class='queueImageHolder'></div>
<div class='indicator num_of_pde_tray_items'></div>
</div>
<div class='clearfix'></div>
</div>
<div class='menuItem bottomMenu' id='pde_tray'>
<div class='inner'>
<div class='heading'>
<div class='title'>
Queue
<span class='indicator num_of_pde_tray_items'></span>
<!-- =pde_tray_count_from_session -->
</div>
<div class='bootstrap closeIcon right' id='pde_tray_close_button'></div>
<div class='clearfix'></div>
</div>
<div class='actions hasItems' id='pde_tray_has_items'>
<div class='selection'>
<div class='trayCheckHolder'>
<input id='pde_tray_select_all' type='checkbox'>
</div>
Select All
</div>
<div class='tools'>
<a onclick='javascript:PDETray_default.downloadSelection();'>
Print/Download
</a>
|
<a onclick='javascript:PDETray_default.emailSelection();'>
Email
</a>
|
<a onclick='javascript:PDETray_default.workspaceSelection();'>
+ Workspace
</a>
|
<a onclick='javascript:PDETray_default.deleteSelection();'>
Delete
</a>
</div>
<div class='clearfix'></div>
</div>
<div class='actions noItems' id='pde_tray_no_items'>
<div class='title'>
You have no items in your Queue
</div>
<div class='clearfix'></div>
</div>
<div class='itemsHolder' id='pde_tray_items'></div>
</div>
</div>

<div class='maskOverlay' id='pde_tray_mask'></div>

<script language='javascript'>
var SHOW_AUDIT = false;
var ROOT_PATH = "/";
var RAILS_ROOT = "/";
var CONTEXT_PATH = "/";
var DOC_ROOT_PATH = "/s/opinion/55b1904f2846408357ee26266414a254/";
var RESULTS_ROOT_PATH = "/search/results/";
var SELECTED_CONTEXT = "";
var MODULE_PATH;
MODULE_PATH = "/document";
var CRUMB_ID = "55b1904f2846408357ee26266414a254";
var BILLING_CONFIGURATION = {"DOCKET":true,"NEWS":false,"LAW":true,"ADVANCED_LEGAL":true,"PATENT":true,"PATENT_ASSIGNMENT":true,"PEOPLE":false,"OPINION":true,"CITATION":false,"BREAKING":true,"DOCKET_REQUESTS":true,"COMPANY_FILINGS_EDGAR":false,"COMPANY_FILINGS_DOCKETS":false,"COMPANY_FILINGS_OTHER":false,"CORP_ACTIONS":true,"ECO_SEARCH":true,"EDGAR_SEARCH":true,"EXAMPLE_DOCUMENTS":true,"CLAUSE_SEARCH":true,"LEG":true,"REG":true,"BOOLEAN":false,"SIMPLE":false,"COMPANY_DOCKETS":true,"TOC_SEARCH":true,"IMMUTABLE_LAW_SEARCH":true};
var CONTEXT_BILLING_POLICY_KEY = "";
var ELITE_ENABLED = false;
var CLIENT_MATTER_PROMPT_ENABLED = false;
var CLIENT_MATTER_ON_LOGIN_ENABLED = false;
var SUPPRESS_CLIENT_MATTER_PROMPT = false;
var clientMatterActive = false;
var currentClientMatter = '';
var currentAttorneyNumber = '';
var clientMatterHaltedForm = null;
var USER_ID = 'un=373038066';
var SESSION_ID = '63166_a5929cc15e1bfd637ed52768bec5d196';
var NTPT_REDIRECTED_EVENT = '';
var NTPT_PGEXTRA = '&activityType=ENTITY&subActivityType=DOCUMENT_VIEWED&pageId=&activityInstanceId=ENTITYa03608&previousPageId=&previousActivityInstanceId=ENTITY703c59&previousActivityType=ENTITY&previousSubActivityType=DOCUMENT_VIEWED&previousActivityTime=2014-02-02T00:44:26-05:00';
var NTPT_GLBLEXTRA = 'un=373038066&sessionId=63166_a5929cc15e1bfd637ed52768bec5d196&auth=true';
var BROWSER_COMPATIBILITY_WARNING = 'false';
var SHOW_MODAL = false;
var JUG;
$(document).ready(function(){
setTimeout(framework_getPageState,500);
framework_bindGlobalResizeElements();
notepad_onDocumentLoaded();
<!-- /DRQS 24932463 -->
$("#downloadPopupLinkForm a").removeAttr("href");
$('#startClientMatterSessionForm').submit(function() {
  createClientMatterSessionFromForm(this);
  return false;
});

var t = $('.clientMattersTableEl');

jQuery.each(t, function(name, value) {
  try {
    var this_value =  $.trim(String(value.innerHTML));
    var this_final_value = this_value.length > 22 ? this_value.substring(0,9)+"..." : this_value;
    value.innerHTML = this_final_value;
  } catch (e) {}
});

$('#startClientMatterSessionForm .recentlyUsed td').click(function() {
  $('#client_matter_label').val($.trim($(this).attr("title")));
});

});
</script>
<script type='text/javascript'>
DOCUMENT_SHOW_SIDEBAR="true";
DOCUMENT_HAS_SIDEBAR_INFO="true";
DOCUMENT_IS_IFRAME="";
NTPT_PGEXTRA = 'documentSearchType=OPINION&docId=X1HF6K0003&docType=OPINIONS&contentClass=LEGAL&activityType=ENTITY&subActivityType=DOCUMENT_VIEWED&pageId=&activityInstanceId=ENTITY703c59&previousPageId=&previousActivityInstanceId=ENTITY0e75a3&previousActivityType=ENTITY&previousSubActivityType=DOCUMENT_VIEWED&previousActivityTime=2014-02-02T00:44:22-05:00';
FLUID_LAYOUT="false";
FULL_DOC_ID = 'X1HF6K0003';
NOTEPAD_UUID="11082191";
NOTEPAD_DOC_ID="X1HF6K0003";
$('#page_loader').show().spin();
JUDGE_IDS=["3659368","3661169"];
JUDGE_NAMES=null;
</script>

<script src="/javascripts/activity_tracking/ni.js?1376494218" type="text/javascript"></script>
<script src="/javascripts/activity_tracking/tracking.js?1384975732" type="text/javascript"></script>
<div class='footer'>
<div class='footerContent printHide'>
<div class='logoContainer grid eight'>
<div class='copyright'>
&copy; 2014 The Bureau of National Affairs, Inc. All Rights Reserved.
 | 
<a href="#" class="menuLink" onclick="open_tos_or_privacy('X3BPR08'); return false;">Terms of Service</a>
 | 
<a href="#" class="menuLink" onclick="open_tos_or_privacy('X3BPH08'); return false;">Privacy Policy</a>
</div>
<a class='logo' href='/home'></a>
<div class='version'>
2.
231154
Gem
0.176.7
231497
 - 3.0.20
</div>
<div class='helpContainer'>
<div class='helpDesk'></div>
<a href="/help/BLAWHelpSystem.htm#Contact_Us.htm" class="menuLink">Submit Feedback</a>
 | 
<a href="mailto:blawhelp@bna.com" class="menuLink">blawhelp@bna.com</a>
</div>
</div>
</div>

</div>
</div>
</body>
</html>
